Author Index to CGC Volumes 72–78

A
Abbas F, 73:142
Abeliovich D, 76:70
Advani SH, 77:91
Akasaka T, 72:33
Al-Asiri RH, 76:151
Al-Sedairy S, 77:14
Alberts D, 73:33
Alimena G, 73:1
Allegranza A, 74:25
Allen EF, 78:239
Altungoz O, 77:69
Aly MS, 73:53
Amada S, 73:95
Aman P, 72:155; 73:79; 76:29
Amano H, 72:33
Amiel A, 73:130; 73:165; 76:59
Amy J-J, 75:120
Andersen JA, 72:146; 75:158; 78:200
Andersen TI, 75:1
Andreeff M, 77:39
André FS, 73:152
Andrén-Sandberg Å, 76:15; 76:29
Angioni A, 74:144
Antonucci A, 78:153
Arbustini E, 75:26
Ariizumi-Shibusawa C, 73:161
Arima T, 73:95
Arranz E, 74:71
Arthur D, 73:1
Asaka A, 73:161
Atkin NB, 74:153
Augustus M, 78:72
Aurias A, 74:13
Aventín A, 78:112
Ayraud N, 76:1

B
Babińska M, 72:141
Bailie KEM, 76:159
Bak-Jensen E, 76:15; 76:29
Baker GF, 76:154
Baker MC, 74:153
Balboni M, 77:33
Balemans M, 73:89
Balloni P, 74:144
Balogh E, 76:72
Balsara B, 77:91
Balus L, 72:96
Barbata G, 75:153
Bardi G, 75:158; 76:15; 76:29; 76:77; 78:200
Barrett JC, 74:99
Barrios C, 76:47
Bartels H, 75:74; 78:15; 78:236
Bartnitzke S, 73:75; 76:145; 77:19; 78:102
Batsakis JG, 76:96
Baugh O, 74:147
Bauters F, 74:115; 76:10
Behm F, 75:139
Beishuizen A, 74:87
Belge G, 78:102
Bell JM, 76:39, 76:154
Bello MJ, 72:55; 73:122
Bellomo MJ, 78:219
Ben-Neriah S, 76:70
Bende M, 76:129
Benedet JL, 77:45
Benitez J, 74:71
Benkhalifa M, 73:8
Bennett JM, 78:23
Berean K, 75:133; 77:45
Berg Evd, 76:100
Berger R, 73:1; 73:65; 74:150
Beris P, 78:219
Bernardi A, 76:106
Bernardi F, 74:115; 76:10
Bernstein R, 78:82
Besses C, 75:72
Betts DR, 74:147
Bhargava MK, 78:99
Bhatia S, 78:68
Bignon Y-J, 76:148
Bigoni R, 77:33
Billson AL, 73:171
Billström R, 74:62
Biondi A, 73:103
Birch JM, 72:28
Björkman A, 76:29
Björkqvist A-M, 78:78
Blair V, 72:28
Blij-Philipsen Mvd, 74:87
Bloomfield CD, 73:1
Bock S, 78:175
Boghosian-Sell L, 72:109
Bonet C, 75:72; 76:36
Bonk U, 73:75
Boop FA, 74:132
Borresen A-L, 75:1; 75:45
Borrow J, 74:50
Bouchot C, 76:1
Bouck NP, 73:109
Bourgain C, 78:53
Bourgeois CA, 78:87
Bozola AR, 73:152
Brem H, 78:46
Brennan MF, 78:138
Briand P, 78:189
Bridge JA, 75:23; 75:156
Brizard A, 73:84
Brizard F, 73:84
Brogger A, 75:1
Broggi G, 74:139; 75:77
Brothman AR, 75:40
Brown JL, 72:116
Brown S, 75:117
Bruzzone R, 72:24; 73:57; 78:7
Bugiani O, 75:77
Bullerdiek J, 73:75; 76:145; 77:19; 78:102
Burgess A, 73:33
Bush CH, 72:59
Buss D, 75:117
Butler MG, 74:95

C
Cabanillas F, 77:39
Cabello P, 76:136
Cajola L, 74:139
Cajulis TR, 77:50
Calabrese G, 78:153
Calasanz MJ, 73:169; 78:210
Caldeira LF, 73:152
Călin G, 75:103
Callahan R, 76:106
Campbell J, 73:142
Cannizzaro LA, 72:109
Cano J, 76:112
Cappa APM, 76:106
Capra E, 75:26
Caradonna F, 75:153
Carbone P, 75:153
Carlén B, 73:147
Carli MG, 77:33
Carpenter PM, 77:50; 78:82
Carroll AJ, 75:6; 75:139
Carson B, 78:46
Casalone R, 74:25
Caselitz J, 76:145
Cassiman JJ, 76:140
Castedo S, 75:45
Castelain P, 78:53
Castilho WH, 73:152
Castoldi G, 77:33
Castresana JS, 76:47
Cepulić M, 76:125
Cerdá-Nijcolás M, 75:150
Chadduck WM, 74:132
Chaganti RSK, 77:60
Chakravarti A, 74:54
Chan AYY, 72:86; 72:92
Chan LC, 72:83; 72:86; 72:92; 76:116; 76:118; 77:89
Chatel M, 72:160
Chattopadhyay P, 78:68
Chauveinc L, 76:85
Chen P, 76:43
Chen Q, 78:138
Chen Y-C, 74:40
Chen Z, 72:73; 78:10
Cheng D, 77:89
Cheung A, 77:89
Ching LM, 72:83; 76:118
Choux M, 78:1
Chow J-M, 74:40
Chuang S-M, 74:40
Cigudosa JC, 73:169; 78:210
Cimino R, 75:106
Cirenei N, 75:77
Cohen IJ, 75:11
Coindre J-M, 76:1
Colită D, 75:103
Colombo BM, 74:139; 75:77
Conti AMF, 75:77
Cooper J, 78:36
Cordoba JC, 72:151
Cortinovis M, 75:26
Cortinovis R, 75:26
Cosson A, 74:115
Cotter F, 74:50
Cropp CS, 76:106
Crowson ML, 76:39
Crussi FG, 78:214
Cuesta B, 73:169
Cuneo A, 77:33

Cunningham D, 76:93
Currie JL, 73:142

D
d'Agay M-F, 73:65
Dahir GA, 74:95
Dahl RJ, 72:137
Dahlenfors R, 76:129
Dal Cin P, 73:53; 78:232
Dam A, 72:126; 76:100
Dangel A, 78:94; 78:172
David L, 75:45
Davis G, 78:172
de Campos JM, 72:55; 73:122
de Groot N, 73:82
de Jong B, 72:126; 73:11; 76:100
de la Chapelle A, 73:1
de Laat AJM, 73:60
De Laurenzi A, 74:144
de Leeuw B, 73:89
De Potter P, 72:109
De Sutter P, 75:120
De Wever I, 78:232
De Wolf-Peeters C, 76:140
Debiec-Rychter M, 72:141
Decker H-JH, 77:1
Deger RB, 78:105
Deisseroth AB, 74:8
Dejana AM, 72:24
Deka R, 74:54
Del Porto G, 72:96
del Potro E, 78:160
Delattre J-Y, 72:130; 76:85
Delattre O, 74:13
Deneffe G, 73:53
Desai ZR, 76:159
Desmaze C, 74:13
Dewald G, 73:1
Di Lorenzo R, 78:153
Di Rosa C, 72:96
DiDonato S, 75:77
Diegoli M, 75:26
Diella F, 76:106
Dietrich CU, 72:146; 75:158; 78:200
Dijkhuizen T, 76:100
Dinda A, 78:68
Dion F, 72:130
DiPaolo JA, 72:39
Dominis M, 76:125
Donner LR, 78:115
Donoso LA, 72:109
Donti E, 78:153
Douglass EC, 72:151
Duffey P, 77:74
Dunn T, 76:19
Dutrillaux A-M, 76:85
Dutrillaux B, 73:23; 74:104; 76:85; 78:87

E
Ebel T, 73:75
Einspenner M, 77:14
El-Naggar AK, 73:134; 76:96
Elizalde AM, 72:65
Ellegaard J, 78:181
Emerson J, 73:33
Endo S, 74:99
Engel H, 77:39
Ensign LG, 73:134
Erickson S, 76:39
Escudier S, 77:39
Espadaler M, 78:112
Espinós D, 78:160
Etxaniz A, 78:210
Evans J, 75:64

F
Facon T, 74:115; 76:10
Farrell Á, 76:43
Faruqi SA, 78:105
Fasanaro A, 75:106
Fejgin M, 73:130; 73:165; 76:59
Fenaux P, 74:150; 78:108
Feng X-L, 74:120
Ferrara F, 75:106
Ferro MT, 76:136; 78:160
Ferster A, 74:59
Finocchiaro G, 74:139; 75:77
Flactif M, 76:10; 78:108
Fletcher JA, 72:79; 77:81
Florenes A, 78:165
Florensa L, 75:72; 75:130; 76:36
Fodstad O, 78:165
Fonck Y, 73:8
Forus A, 78:145; 78:165
Fox S, 73:33
Fraccaro M, 75:26
Franchi PG, 78:153
Friz A, 72:101
Fu S-B, 74:120
Fugazza G, 72:24; 73:57; 78:7
Fujieda H, 73:69
Fujimura T, 78:64
Fujitake H, 74:35

G
Gaber E, 73:165
Gad GS, 75:139
Gallego M, 75:139
Galli C, 75:77
Gambarelli D, 78:1
García-Sagredo JM, 76:136; 78:160
Garson OM, 73:1; 78:36
Gasques JAL, 73:152
Gattamaneni HR, 72:28
Gaudray P, 72:160
Gebhardt MC, 77:81
Gebhart E, 72:101
Gemmill RM, 77:1
Genitori L, 78:1
Gentet JC, 78:1
George DL, 76:23
George R, 75:64
Geurts van Kessel A, 72:105; 73:11; 73:89; 78:145
Ghosh M, 78:68
Gibaud A, 78:87
Gibbons B, 74:147
Giovannelli L, 74:144
Girjes A, 76:43
Girodet J, 74:104
Gladstone BR, 77:91
Gogineni SK, 72:65
Gohla G, 73:75
Gohma I, 72:33
Gollin SM, 73:157
Gómez L, 76:47
Gonik B, 73:82
Gonzalez R, 72:16
Gopal R, 77:91
Gorse KM, 75:31
Gorunova L, 76:15; 77:26
Goshen R, 73:82
Goshen Y, 75:11
Gramatzki M, 72:101
Grammatico B, 72:96
Grammatico P, 72:96
Granata G, 75:153
Granata P, 74:25
Graziani N, 78:1
Green J, 77:1
Griffin CA, 73:142; 74:30; 77:55; 78:46
Grisoli F, 78:1
Grote W, 78:15; 78:236
Guan X-Y, 73:33
Guerneri S, 75:77
Guilhot F, 73:84
Guitard A, 73:86
Gullón A, 73:169; 78:210
Gustafsson H, 74:77

H
Ha SY, 76:116; 76:118
Haarbrink M, 73:60
Haesen S, 75:120
Hagag N, 76:19
Hagemeijer A, 73:1; 73:60; 74:87
Haller E, 78:219
Hämäläinen E, 78:28
Hamamoto K, 74:35
Han K, 72:78; 74:19
Hannan M, 77:14
Harbott J, 73:103
Harnish PR, 76:23
Harris CP, 72:78; 74:19
Harris M, 72:28
Harrison K, 76:33
Harrison KJ, 76:33
Hartley AL, 72:28
Hashimoto K, 72:75
Hashimoto-Ninomiya A, 74:35
Hawkins AL, 74:30
Hayashi R, 74:30
Head D, 75:139
Hebert J, 73:65
Hecht BK, 72:160
Hecht F, 72:160; 76:1
Heim S, 72:146; 73:79; 75:158; 76:15; 76:29; 76:77; 77:26; 78:200
Heinonen K, 78:28
Heppner P, 78:175
Herath SE, 72:137
Herrmann ME, 75:111
Heyderman E, 75:90
Hickish T, 76:93
Hiemann P, 74:59
Higurashi M, 73:161
Hill D, 77:39
Himmler A, 78:15
Hirano M, 74:84
Hobson K, 76:43
Hochberg A, 73:82
Hoffner L, 74:54
Högemann I, 78:175
Hor F, 76:85
Horiike S, 74:35
Horsman D, 75:133; 77:45
Hossfeld DK, 73:17
Howe K, 74:50
Hruban RH, 77:55; 78:46
Hrynchak M, 75:133; 77:45
Hunyadi K, 76:72
Hurd D, 75:117
Huret JL, 73:84
Husain M, 74:132

I
Iijima S, 73:161
Imamura T, 73:95
Imanaka T, 72:33
Inatomi Y, 73:69
Ino T, 74:84

Ironside P, 78:36
Irriguible D, 75:130
Isayama T, 76:157
Ishibashi Y, 73:161
Ishiguro M, 76:157
Ito H, 75:60
Iwasaki H, 76:157
Izydorczyk V, 74:115

J
Jacobs SM, 75:31
Jaffe E, 77:74
Jalihal S, 73:171
Jani K, 74:50
Jeison M, 75:11
Jendiroba D, 77:39
Jenkins RB, 72:137
Jess H, 76:159
Jhanwar SC, 78:138
Jin Y, 75:158
Jiskoot P, 73:53
Johansson B, 73:79; 74:62; 75:158; 76:15; 76:29; 76:50
Jones PHM, 72:28
Jonsson N, 77:26
Jonveaux P, 73:65; 74:150
Juberg-Ode M, 74:77
Juneja S, 78:36
Jurukovski V, 74:109

K
Kadam PR, 77:91
Kalousek DK, 76:33
Kaneko Y, 76:157
Kang C, 74:19
Kaplinsky C, 75:11
Karakousis C, 77:69
Kasama M, 73:46
Katz R, 77:39
Kawakubo K, 72:48; 73:69; 78:40; 78:64
Kawasaki-Oyama RS, 73:152
Kazmierczak B, 77:19
Kearney L, 74:50
Kelsey AM, 72:28
Kémény J-L, 73:8
Kempski H, 74:50
Kennedy SJ, 75:31
Khoobyarian N, 74:123
Killary A, 76:96
Kimura N, 72:48; 73:69; 78:40
Kimura T, 74:35
Kindblom LG, 73:89
Kirsch-Volders M, 75:120; 78:53
Kishimoto Y, 74:35
Klauck SM, 77:1
Klein KG, 73:109
Kletzel M, 78:214
Knutsen T, 77:74
Knuutila S, 72:1; 78:78
Kodama S, 74:99
Köhler M, 73:79
Kojima H, 74:84
Kokalj-Vokac N, 78:87
Kondo T, 73:46
Koops HS, 76:100
Kouides PA, 78:23
Kozakewich HP, 77:81
Krauß M, 72:101
Kreicbergs A, 73:147; 76:47
Krous HF, 77:50
Kruskic M, 74:109
Kunhi M, 77:14
Kusak ME, 72:55; 73:122
Kuse R, 78:15
Kwong YL, 72:83; 72:86; 72:92

L
Laï JL, 74:115; 76:10; 78:108
Lalkin A, 73:165
Lalle P, 76:148
Lalley PA, 75:111
Lam CK, 72:86
Lambrechts AC, 74:87
Lampert F, 73:103; 78:242
Langerak AW, 73:60
Larramendy ML, 72:1; 78:78
Larsson C, 73:11
Latham M, 73:171
Lau YL, 76:118
Lautier A, 73:8
Lavin M, 76:43
Lawler SD, 73:1
Lawrence JB, 77:1
Lee CP, 76:118
Lee F-Y, 74:40
Lee K, 74:19
Lee W, 72:78; 74:19
Lena G, 78:1
Leong SPL, 77:69
Leroux A, 76:1
Lessard M, 73:84
Leung NK, 76:118
Leuschner E, 73:75; 76:145
Li FP, 78:138
Li P, 74:120
Li-zhen H, 76:65
Lian-huang L, 76:65
Liang JC, 74:8
Liang RHS, 72:83
Liberati AM, 78:153
Liberski PP, 72:141
Lie AKW, 72:86
Liehr T, 72:101
Lier ME, 75:1
Limon J, 72:141; 76:15
Lin D-T, 74:40
Lin F, 78:82
Lin K-H, 74:40
Ling MP, 75:6
Liscia DS, 76:106
Lishner M, 73:165
Liu C-X, 74:120
Liu HW, 72:83
Liu M-C, 74:40
Liu Q-Z, 74:120
Liu Y, 73:33
Llonbart-Bosch A, 75:150
Lo R, 74:30, 77:55
Long PP, 73:142; 77:55; 78:46
Longo DL, 77:74
Look AT, 74:30
López-Ginés C, 75:150
López-Yarto A, 76:136
Lorberboum-Galski H, 76:59
Losada AP, 75:130; 76:36
Lovell M, 76:96
Lu X, 74:8
Ludoski M, 74:109
Ludvigsson J, 73:79
Lukášová M, 72:68
Lukeis R, 72:116; 78:36
Lunde JH, 78:239
Lynch HT, 78:94

M
Macera MJ, 72:65
Madsen MW, 78:189
Maelandsmo GM, 78:165
Maglia O, 73:103
Magnani I, 75:77
Mahlamäki E, 78:28
Makar R, 73:33
Malet P, 73:8
Malfoy B, 78:87
Mandahl N, 72:155; 73:147; 75:158; 76:15; 76:29; 77:26; 78:127
Manor Y, 73:165
Maraví J, 75:145
Marczynska B, 74:123
Marin J, 78:210
Mark HFL, 76:158
Mark J, 76:129
Marks J, 76:23
Marottoli V, 75:106
Martin K, 73:171
Martín-Henao GA, 78:112
Marynen P, 73:53
Mascarello JT, 77:50
Masera G, 73:103
Masui S, 76:33
Masuya M, 72:33
Matthews J, 78:36
Mattson K, 78:78
Mauritzson N, 74:62
Mayayo M, 76:136
McLachlan J, 74:99
McManus AP, 76:159
McMaster TJ, 76:93
McNeil J, 77:1
Mecucci C, 74:144; 76:140; 78:112
Medchill MT, 78:172
Mediavilla J, 78:160
Meisner LF, 72:78; 74:19
Meloni AM, 72:59; 73:89; 74:73; 77:69; 78:94; 78:192; 78:207
Melot T, 74:13
Mensink HJA, 72:126
Merlo GR, 76:106
Meroni E, 74:25
Mertens F, 73:147; 77:26
Meyer WH, 72:151
Meyer-Bolte K, 76:145
Miano C, 74:144
Michalová J, 72:68
Michel G, 73:86
Mićić S, 72:157
Milašin J, 72:157
Miles MJ, 76:93
Miller N, 78:46
Min T, 76:93
Minelli E, 74:25
Miozzo M, 76:1
Mirro J, 73:157
Mitelman F, 72:155; 73:1; 73:79; 73:147; 74:62; 75:158; 76:15; 76:29; 77:26; 78:127
Mitra AB, 76:56
Miura AB, 72:75
Miura I, 72:75
Miura S, 72:75
Miyauchi J, 73:69
Miyazaki H, 74:84
Miyoshi J, 75:51
Molenaar WA, 73:89

Molenaar WM, 72:126; 73:11; 76:100
Mononen I, 78:28
Montpellier C, 78:87
Moore GE, 72:16
Morgan R, 72:44; 72:73; 78:10; 78:207
Morimoto K, 73:161
Morizio E, 78:153
Morsberger LA, 77:55
Morse HG, 72:16
Morton CC, 77:65
Mossafa H, 73:84
Moyret C, 76:148
Mozziconacci M, 73:86
Muenke M, 76:23
Muleris M, 73:23; 74:104; 78:87
Müller H, 75:67
Muñoz R, 76:136
Murakami T, 72:48
Murphy ME, 76:23
Musilová J, 72:68
Myklebost O, 78:165

N
Naeem R, 72:79
Nagarajan L, 74:8
Nagler A, 73:130; 76:59
Nakamura T, 72:33
Nakamura Y, 73:11
Nakazawa S, 72:48; 73:69; 78:40; 78:64
Nakić M, 76:125
Nasrin N, 77:14
Nedoszytko B, 72:141; 76:15
Neff JR, 75:23
Nesland JM, 75:1
Neumann E, 76:33
Neumann HHP, 77:1
Newbold R, 74:99
Niazi M, 76:151
Nicoară S, 75:103
Nicolo G, 76:1
Nielsen KV, 78:189
Niezabitowski A, 76:15
Nilbert M, 72:155
Nimura T, 72:75
Nishinari T, 72:75
Niveleau A, 78:87
Nomura T, 74:84
Nordkvist A, 74:77; 76:129
Norman MG, 76:33
Noumoff JS, 78:105
Nousiainen T, 78:28
Novak A, 74:109
Novales MA, 75:145
Nylund SJ, 72:1

O
O'Connor M, 75:117
Odero MD, 78:210
Ohjimi Y, 76:157
Ohmura K-i, 72:33
Ohno H, 72:33
Ohno Y-i, 72:33
Ohyashiki JH, 72:48; 73:69; 78:40; 78:64
Ohyashiki K, 72:48; 73:69; 78:40; 78:64
Okada K, 75:60
Oláh É, 76:72
Olde Weghuis DEM, 73:11; 73:89; 78:145
Oliveros O, 76:112
Ondreyco S, 72:44
Oosten HR, 72:105
Oosterhuis JW, 73:11; 76:100
Or R, 76:59; 76:70
Örndal C, 78:127
Ortiz LM, 72:16
Otsuka F, 73:161
Ozisik YY, 74:73; 77:69; 78:207

P
Palividis Z, 72:116
Palka G, 78:153
Pandis N, 72:146; 75:158; 76:15; 76:29; 76:77; 78:200
Pang J, 72:83
Paone G, 75:106
Pappo A, 75:139
Parham DM, 72:151
Parikh PM, 77:91
Parisi JE, 72:137
Parlier V, 78:219
Parrington JM, 75:90
Parsons EA, 76:39
Pathak S, 73:134
Patrone F, 72:24; 73:57
Pazzi I, 77:33
Pearson ADJ, 75:64
Pedersen B, 78:181
Pedersen-Bjergaard J, 76:50
Pedeutour F, 76:1
Peier A, 77:69; 78:207
Peila R, 78:153
Penchansky L, 73:157
Pérez C, 73:169
Pérez I, 76:136
Perez-Losada A, 75:72
Perissel B, 73:8
Perlman E, 74:30
Persson B, 77:26
Pestaña A, 72:55; 73:122
Petersson C, 78:200
Petković I, 76:125
Petrides PE, 78:175
Pettenati MJ, 75:6; 75:117
Phatak PD, 78:23
Philip P, 76:50
Pickering D, 75:23
Poisson M, 72:130; 76:85
Pollo B, 74:139; 75:77
Popescu NC, 72:161
Popescu ND, 72:39
Portentoso P, 74:25
Potocki L, 74:66
Powell D, 73:33
Praissman L, 76:19
Pratap M, 76:56
Previati R, 77:33
Prieto E, 74:71
Prosper F, 78:210
Pruchon E, 76:85
Pullen DJ, 75:6
Pykett MJ, 76:23

R
Rabinowitz AP, 75:147
Raffeld M, 77:74
Raghavan D, 72:116
Raimondi SC, 75:139
Rao N, 75:6
Rao PH, 76:56; 77:60
Rao PN, 75:117
Rao SK, 74:66
Ratner S, 75:111
Ravid M, 73:165
Ravindranath Y, 75:139
Raybaud C, 78:1
Reeves BR, 74:50
Reid MM, 75:64
Rein MS, 77:65
Resino M, 76:136; 78:160
Rey J-P, 75:67
Rey JA, 72:55; 73:122
Reynaud C, 78:87
Richard F, 73:23
Ricoul M, 76:85
Riehm H, 73:103
Rifón J, 73:169; 78:210
Righi R, 74:25
Riske CB, 72:44
Ritterbach J, 73:103
Roberti G, 77:33
Robinson WA, 72:16
Rocha E, 78:210
Rodriguez MA, 77:39
Rogalla P, 77:19
Rohen C, 77:19
Rohr LR, 75:40
Roque L, 78:145
Rosati D, 74:144
Rosenberg C, 75:1
Rosenshein N, 73:142
Rouleau GA, 72:130
Rowley JD, 73:1
Ruscio C, 74:144
Russell PJ, 72:116
Rydholm A, 72:155; 73:147; 78:127
Rydstedt LL, 75:111
Rys J, 76:15

S
Sabatier L, 76:85
Saito M, 78:64
Sakai N, 75:60
Sakurai M, 73:1
Salmon R-J, 74:104
Salski C, 77:45
Sammartino G, 74:132; 76:154
San Martín MV, 75:145
San Román C, 76:136; 78:160
Sanchez MA, 72:65
Sandberg AA, 72:44; 72:59; 72:73; 73:89; 74:73; 77:1; 77:69; 78:10; 78:94; 78:172; 78:207
Sans-Sabrafen J, 75:130
Sarasa JL, 72:55; 73:122
Sargent MS, 77:65
Sariban E, 74:59
Sarkar C, 78:68
Sawyer JR, 74:132; 76:39; 76:154; 78:214
Scappaticci S, 75:26
Scarpa S, 72:96
Schantz SP, 77:60
Schlegelberger B, 75:74; 78:15; 78:236
Schmidt PM, 78:219
Schrier PI, 73:60
Schwartz HS, 74:95
Schwenn MR, 74:66
Sciot R, 78:232
Scott R, 75:67
Segers P, 75:120
Seizinger BR, 77:1
Seruca R, 75:45
Sessarego M, 72:24; 73:57; 78:7
Shah NK, 73:142
Shearin JP, 74:66
Shekhter-Levin S, 73:157
Shen M-C, 74:40
Sherer ME, 73:157
Shi G, 73:17

Shields CL, 72:109
Shields JA, 72:109
Shimamoto T, 73:69; 78:64
Shimizu K, 73:161
Shing MK, 72:92
Shinoura N, 73:46
Shirota T, 75:60
Shohat M, 75:11
Shuster JJ, 75:6
Siciliano M, 74:8
Siepman A, 72:105; 78:145
Silvestri I, 75:106
Simon B, 77:1
Simsiman RC, 74:19
Singh AD, 72:109
Sinha S, 78:68
Sinke RJ, 73:11; 78:145
Sinovic J, 75:156
Sjögren HO, 76:29
Slavin S, 73:130; 76:59
Smilde TJ, 74:87
Smit EME, 74:87
Smith D, 77:1
Smith S, 76:39
Soares J, 78:145
Sobrinho-Simões M, 75:45
Sobue R, 74:84
Sole F, 75:72; 75:130; 76:36
Solero CL, 74:25
Solomon E, 74:50
Soukhikh T, 78:200
Sozzi G, 76:1
Spadano A, 78:153
Spanier SS, 72:59
Sreekantaiah C, 77:60
Staats B, 73:75
Stalboerger PG, 72:137
Stark B, 75:11
Starý J, 72:68
Stefănescu DT, 75:103
Stellink F, 72:105; 78:145
Stenman G, 73:89; 74:77; 76:129
Sterry W, 75:74, 78:15
Steuber CP, 75:6
Stone JF, 72:59; 72:73; 74:73; 78:10
Stuppia L, 78:153
Suijkerbuijk RF, 73:11; 73:89; 78:145
Sundareshan TS, 78:72
Surti U, 74:54; 74:73
Suzuki K, 75:51
Swansbury GJ, 73:1
Szadowska A, 72:141

T
Taavitsainen M, 78:78
Taetle R, 73:33
Taillandier J, 73:8
Tajara EH, 73:152
Takeichi M, 75:60
Takeshita T, 73:161
Talpos GB, 75:111
Tammilehto L, 78:78
Tan L, 78:36
Tanigami A, 73:11
Tanzer J, 73:84
Tauchi T, 72:48; 78:40
Teixeira MR, 78:200
Tenan M, 74:139
Thode B, 78:102
Thomas G, 74:13
Thomé JA, 73:152
Thompson FH, 73:33
Thuret I, 73:86
Tien H-F, 74:40
Tobler A, 78:219
Toma S, 76:1
Tosi S, 73:103
Townes PL, 74:66
Toyama K, 72:48; 73:69; 78:40; 78:64
Trams G, 77:19
Trautmann U, 72:101
Trent J, 73:33
Trigo MI, 75:145
Trillot N, 76:10
Tsuneyoshi M, 73:95
Turc-Carel C, 72:160; 76:1
Tuzuki M, 74:84

U
Uchida H, 75:60
Udayakumar AM, 78:99

V
Vagner-Capodano AM, 73:86; 78:1
Validire P, 74:104
Vallcorba I, 76:136
Vallespi T, 75:130
Vamos E, 74:59
Van Dam P, 75:120
Van Damme B, 78:232
van de Kaa C, 78:145
van de Klundert W, 72:105
van Dekken HD, 73:134
van den Berg E, 72:126; 73:89
van den Berg-Bakker LAM, 73:60
Van Den Berghe H, 73:1; 73:53; 76:140; 78:232
van der Kwast TH, 73:60
Van Dijken PJ, 76:151
van Echten J, 72:126
van Gaal J, 72:105
van Melle G, 78:219
van Ooteghem RBC, 74:87
Vaquero J, 72:55; 73:122
Varesco L, 72:96
Vázquez-Mazariego Y, 76:136
Vega F, 76:85
Veiga I, 75:45
Venesio T, 76:106
Verdoodt B, 78:53
Verhoef G, 76:140
Verma RS, 72:65
Versnel MA, 73:60
Vila J, 75:130
Villegas A, 78:160
Viola MV, 76:19
Vnencak-Jones CL, 74:95
Vogel R, 75:11
Volz P, 78:46

W
Wake N, 73:95
Wakita M, 74:84
Wald N, 73:157
Walker DA, 73:171
Wan TM, 72:92
Wang C-H, 74:40
Wang M-R, 73:8
Wang N, 74:1; 78:23
Warrington JA, 74:8
Wary KK, 72:109
Wasmuth JJ, 74:8
Wass J, 72:116
Watanabe M, 75:51
Watkins D, 72:130
Watson MJ, 75:40
Weber G, 73:11
Weber-Matthiesen K, 78:236
Wechsler DS, 74:30
Weh H-J, 73:17
Weier HU, 76:140
Weinstein R, 73:33
Weremowicz S, 77:65
Wessman M, 72:1
West LF, 75:90
Westin EH, 75:31
Whang-Peng J, 77:74
White V, 75:133
Wiersema J, 76:100
Willén H, 73:147; 78:127
Williams BJ, 75:40
Wlodarska I, 76:140
Woda BA, 74:66
Woessner S, 75:72; 75:130; 76:36
Wofford M, 75:6
Wolman SR, 75:111
Wong KF, 72:92
Woodruff JM, 78:138

X
Xu J, 74:1

Y
Yamada K, 73:46
Yamagata Z, 73:161
Yaniv I, 75:11
Yarkoni S, 73:130; 73:165; 76:59
Yasunaga K, 74:35
Yehuda O, 76:70
Yeo CJ, 77:55
Yoshioka M, 73:46
Younes A, 77:39
Yuen PMP, 72:92; 76:118
Yunis E, 76:112

Z
Zafrani B, 74:104
Zaizov R, 75:11
Zandecki M, 74:115; 76:10
Zattara-Cannoni H, 73:86; 78:1
Zeltzer PM, 78:82
Zemanová Z, 72:68
Zhang Y, 78:236
Zhao L, 74:8
Zhao WP, 77:74
Zhi-zhe C, 76:65
Zhu XL, 75:40
Zimonjic DB, 72:39; 72:161
Zucman J, 74:13

Subject Index to CGC Volumes 72–78

Acute Lymphoblastic Leukemia (ALL)
B-cell line with *bcl2* rearrangement, 74:87
cell line (CCRF-CEM), 75:31
childhood, 72:92; 76:118
c-*myb* rearrangement, 75:31
cytogenetics, 76:118
FISH studies, 73:103; 74:144
hypomethylated status in, 78:40
immunophenotypes and cytogenetics, 76:118
inv(14) in, 72:92
i(8q) in B-ALL, 73:84
i(17q) by FISH, 73:17
molecular studies in, 78:40
numerical changes, 73:103
refractory disease, 77:134
T-cell, 72:92
T-cell receptor rearrangements, 78:40
telomeric shortening and genetic changes, 78:64
t(1;19) and t(14;18) in L1, 78:23
t(9;22) in, 76:70
-Y in, 76:70
+5 as sole change, 75:117
+8 and clinical aspects, 75:6
+8 as primary change, 75:6
+8 in ALL, 74:144; 75:6
17p monosomy and refractory disease, 77:134
+19 as sole change, 74:62
Acute Megakaryoblastic Leukemia (M7)
cytogenetic findings in, 74:67
+21 in, 74:66
Acute Monocytic Leukemia (M5)
cytogenetics, 73:1; 74:50
long survival, 73:1
MLL-1 and RARA genes, 74:50
molecular studies, 74:50
t(11;17) in, 74:50
+19 as sole change, 74:62
Acute Myeloblastic Leukemia
biphenotypic, 76:116
granulocytic sarcoma, 78:239
t(9;11)(p22;p15) in M1 (biphenotypic), 76:116
9q- in, 78:239
Acute Myeloblastic Leukemia (M1 and M2)
CD7+: clinical and biologic characteristics, 73:69
cytogenetics, 73:1
granulocytic sarcoma, 74:59
hypodiploidy (severe) in M2, 74:147
immunoglobulin in CD7+, 73:69
in children, 75:139
long survival, 73:1
molecular studies in, 73:69
multiple trisomies in M1, 73:79
M1, biphenotypic, 76:116
T-cell receptors in, 73:69
t(1;7)-unbalanced, 74:35
t(7;12)(p15-21;p12-13) in M1, 73:171
t(8;21)(q22;q22) in M1, 73:79
t(8;21)(q22;q22) in M2, 74:35; 75:139
variant t(8;21) in M2, 75:139
+19 as sole change, 74:62
Acute Myelogenous Leukemia; see Acute Non-lymphocytic Leukemia (ANLL)
Acute Myeloid Leukemia; see Acute Non-lymphocytic Leukemia (ANLL)
Acute Myelomonocytic Leukemia (M4)
cytogenetics, 73:1
interphase study of +11, 77:33
involvement of erythrocytic and granulomonocytic cell in +11, 77:33
long survival, 73:1
i(1;19)(q23;p13) in, 73:86
i(17q) by FISH, 73:17
+11 in, 77:33
+19 as sole change, 74:62
Acute Non-lymphocytic Leukemia (ANLL)
APL, 72:73, 75
CD7+ in, 73:69
cytogenetics, 72:86; 73:1
FISH studies of i(17q), 73:17
genetic predisposition in families, 76:65
granulocytic sarcoma, 74:59
hypomethylated status, 78:40
i(17q) in, 73:17
long survival, 73:1
molecular studies, 78:40
refractory disease, 77:134
secondary in children, 75:11
sex chromosome loss, 72:44
therapy-related in children, 75:11
T-receptor status, 78:40
triclonality, 72:86
t(7;12)(p15-21;p12-13), 73:171
t(8;21) in, 75:139
t(16;21)(p11;q22) in ALL, 75:60 (is ANLL)
t(12;13)(p13;q14) in M0 ANLL, 77:106
X chromosome loss, 72:44
Y chromosome loss, 72:44
+6 as sole anomaly, 74:150
17p monosomy and refractory disease, 77:134
+19 as sole change, 74:62
Acute Promyelocytic Leukemia (APL)
complex t(15;17), 72:73
cytogenetics, 73:1
FISH studies in, 72:73; 78:112

i(17q) in APL, 78:112
long survival, 73:1
secondary leukemia, 74:84
t(8;17) in, 72:75
t(15;17) in, 72:73
variant of t(15;17), 72:75
Additions
chromosomal in ovarian cancer, 73:33
in chordomas, 73:147
Adenoid cystic adenoma
cytogenetics, 75:150
in sphenoidal sinus, 75:150
Adenolipomas
breast, 72:146
cytogenetics of, 72:146
mesenchymal origin, 72:146
Adenoma(s)
colorectal, 74:104
cytogenetics, 74:104
fibroadenoma of breast, 76:145
Adipose tissue tumors
adenolipomas of breast, 72:146
cytogenetic changes in, 72:59
FISH and molecular analysis, 77:162
hibernoma, 72:59
lipoblastoma, 76:39
8q11-13 in lipoblastoma, 78:232
Adrenocortical tumors
chromosome changes, 75:111
11p15 in, 75:111
Anemia
aplastic and BMT, 72:68
Fanconi and BMT, 72:68
Fanconi anemia and apoptosis, 75:67
refractory, 74:71
refractory with excess blasts, 74:8
sideroblastic, 74:71
+14 in sideroblastic refractory, 74:71
Aneuploidy
assessment of, 72:78
FISH in, 72:78
in brain tumors, 73:46
Animal cells and models
cell line of endometrial cancer, 74:99
cytogenetics of endometrial cancer, 74:99
lack of v-*src* involvement in transformed cells, 74:123
lung cancer in mice, 77:153
marmoset cells, 74:123
models for tumorigenesis, 77:152
murine cell lines, 74:99
oncogene activation, 75:51
SCID tumors, 77:153
Syrian hamster cells, 75:51
telomeric association in dog cells, 77:169
Apoptosis
detection by FISH, 77:150
in Fanconi anemia, 75:67
mitomycin C in, 75:67
Ascitic fluid; see Effusions
Astroglial tumors
cytogenetics, 77:180
prognosis, 77:180
Astrocytoma
chromosome changes, 73:46; 75:77; 76:33, 85; 77:181
heterogeneity by cytogenetics, 77:181
LOH in, 74:139
molecular studies, 73:122; 74:139
prognosis and genetics, 77:181
p53 mutations, 74:139
recurrent, 76:85
ros oncogene in, 72:130
satellite analysis, 74:139
satellite association, 76:33
sex chromosome loss, 73:46
Ataxia-Telangiectasia
chromatid damage, 76:43
effects of irradiation on cells, 77:14
familial, 76:43
p53 in cells, 77:14
radiation effects, 76:43

Basal cell carcinoma
cytogenetics, 73:152
Beckwith-Wiedemann syndrome
associated tumors, 77:152
Wilms tumor and LOH, 77:167
11p and childhood tumors, 77:168
11p15 in, 77:168
Biphenotypic leukemia
M1, 76:116
t(9;11)()p22;p15), 76:116
Bladder
cancer cell line, 72:116
carcinoma, 72:116
chromosome changes in diploid tumors, 77:118
chromosome 10 in, 73:8; 77:118
chromosomes 7, 9 and 10, 77:118
comparative genomic hybridization, 77:149
FISH, flow and cytogenetics in papillary cancers, 77:193
FISH studies in, 73:8; 77:118
FISH studies of 11p and 11q, 77:193
heterogeneous transitional carcinoma, 72:116
karyotypic analysis, 72:116
monosomy 9, 77:118
trisomy 7, 77:118
trisomy 10, 77:118
Bone marrow
cytogenetic studies in, 78:10
FISH studies in, 78:10
studies in clinical oncology, 78:10
tumor cells in, 78:10
+5 in long-term cultures, 78:207
+5 in marrow for cancer patients, 78:207
Bone Marrow Transplantation (BMT)
cytogenetics, 72:68
in leukemias, 72:68
in MDS, 72:68
Bone tumors
cytogenetics, 77:81

deletions, rings and dmin, 77:81
osteosarcomas, 77:81
cytogenetics of, 78:115
Brain tumors
chromosome 7, 72:55; 75:77
cytogenetics in gliomas, 72:55; 73:46
ependymomas, 74:132
hemangioblastoma in von Hippel-Lindau syndrome, 77:1
LOH in, 74:139
microsatellite analysis, 74:139
molecular studies in, 72:55, 130; 73:122; 74:139
oncogenes in, 72:130
p53 mutations, 74:139
RFLP analysis in gliomas, 72:55
sex chromosome behavior, 77:157
sex chromosome loss, 72:160; 73:46
Breast tumors
adenolipoma of, 72:146
allelic imbalance at 16q in cancer, 77:169
BCAR-1 studies, 77:185
breast-ovarian gene, 77:154
cancer lines with decreased telomeres, 77:19
cell lines, 76:23; 77:19
CGH in cancers, 77:163
chromosome changes in male tumor, 78:99
chromosome instability in ductal cancer, 77:184
chromosome 1 and DNA content in benign and malignant tumors, 78:53
chromosome 1 in benign and malignant tumors, 77:184
chromosome 1 in cancer, 77:170
chromosome 17 in cancer, 75:1
chromosomes in fibroadenomas, 77:125
Cowden's disease and breast cancer, 77:169
cytogenetics of adenolipomas, 72:146
cytogenetics in cancer, 77:157, 185; 78:99
cytogenetics in fibroadenoma, 76:145; 77:202
fibroadenoma, 76:145; 77:125
FISH studies in cancer, 75:1; 78:53
gene at 17p13.3 distal to p53, 77:170
HSR, 77;149
in benign neoplasms, 77:184
in male, 78:99
karyotypic evolution in cell line, 78:189
karyotypic heterogeneity in tumors, 77:184
medullary cancer, 73:75
molecular studies in cancer, 75:1; 76:23, 106
non-tumorigenic cell line, 78:189
phyllodes tumors, 77:202; 78:200
second suppressor gene on 17p, 76:106
somatostatin genes in cancer, 77:185
suppressor gene on 17p in cancer, 76:106
t(1;16)(q10;p10) as sole change, 75:158
8p loss in breast cancer, 76:23
11q13 and cyclin-D1 in cell line, 77:171
+18 in medullary cancer, 73:75
20q13 locus amplification, 77:158
Burkitt lymphoma
chromosome painting, 76:136
cytogenetics, 76:136
der(8)t(2;8), 76:136
FISH studies, 76:136

Carcinoma
cytogenetics of mucoepidermoid, 74:77; 76:96
FISH studies, 74:77
mucoepidermoid, 74:77; 76:96
primary of salivary gland, 76:96
+5 as sole change, 76:96
11q14-22 in mucoepidermoid, 74:77
Cell
interphase analysis, 72:1, 24
MAC analysis, 72:1
mitotic analysis, 72:1
Cell line(s)
B-ALL with *bcl2* rearrangement, 74:87
bladder cancer, 72:116
breast cancer, 76:23; 77:19
cytogenetic instability in breast cancer cell line, 78:189
endometrial cancer (murine), 74:99
fibrosarcoma, 73:109
human, 74:157
keratinocyte and chromosome 3, 77:189
keratinocyte line, 72:39
monocytic and myelocytic (human), 74:157
myeloperoxidase mRNA in human cell lines, 74:157
non-tumorigenic breast cancer, 78:189
ovarian cancer, 77:99
polyp of colon, 77:171
renal cancer, 78:175
viral integration sites, 72:39
Cervical cancer
cell lines, 77:197
chromosome changes, 74:153; 77:196
chromosome 1 in, 75:120; 77:196
del(6q) in, 76:56
der(17;22)(q10;q10), 74:153
FISH studies in, 75:120; 77:196, 197
i(5p) in, 76:56
premalignant stages, 75:120
11q22-24 and suppressor gene, 77:196
Cholesteatoma
chromosome changes, 77:189
Chondroma
paraosteal, 77:200
12q13 in, 77:200
Chondrosarcoma
cytogenetics, 76:100
histologic subclassification, 76:100
Chordoma(s)
chromosome changes, 73:147; 75:23
molecular studies, 75:23
sacral, 73:147; 75:23
Chromosome
organization, 72:39
painting in Burkitt lymphoma, 76:136
painting in follicular lymphoma, 76:140
painting in multiple myeloma, 76:10

viral integration sites, 72:39
1 in cervical lesions, 75:120
1q in fibrosarcoma, 73:109
3 and cancer, 77:159
3 in lymphoma, 72:33
6p in retinoblastoma, 76:112
7 in gliomas, 72:55
7 in Wilms tumor, 77:93
7q31 and factor suppressing 7q- clone, 78:181
7, 9, 10, 13, 17 and 22 in gliomas, 73:122
8 and 22 in CCS, 72:141
8 in ANLL, 72:101
8p loss in breast cancer, 76:23
8q in lipoblastoma, 76:39
9q in follicular lymphoma, 76:140
10 in bladder cancer, 73:8
11q13 in cancer, 77:155, 171
12 in CLL, 72:83
12 in tumors, 77:160
12q13-15 in solid tumors, 77:161
12q13-15: isolation and mapping of region, 77:176
17 and rings in dermatofibrosarcoma protuberans, 76:1
17 in breast cancer, 75:1; 76:106
Chromosome changes
adenolipomas of breast, 72:146
in ALL, 72:92; 73:103; 75:117; 76:118; 77:134
in ANLL, 72:44, 73, 75, 86, 105; 77:134
in APL, 72:73, 75
in brain tumors, 73:46
in chordomas, 73:147; 75:23
in clear cell sarcoma, 72:141
in CLL, 72:83; 73:65
in CML, 72:48, 65; 105; 73:57
in colorectal adenomas, 74:104
in chondrosarcoma, 76:100
in dermatofibrosarcoma protuberans, 76:1
in endometrial cancer, 73:142
in ependymomas, 74:132
in gallbladder cancer, 76:15
in gliomas, 72:55; 73:46; 75:77; 76:85
in hemangiopericytomas, 72:137
in hibernoma, 72:59
in hidradenoma, 77:26
in lacrimal gland tumors, 75:134
in leiomyoma, 77:65
in MDS, 74:40; 77:134
in melanoma, 77:69
in multiple myeloma, 76:10; 78:210
in neuroblastoma, 74:30
in non-neoplastic solid tissues, 77:183
in osteosarcoma, 77:81
in ovarian cancer, 73:33; 77:99
in pancreatic endocrine tumors, 77:55
in phyllodes tumors of breast, 78:200
in primary MDS, 78:219
in Richter syndrome, 73:65
in salivary gland tumors, 75:137
in sarcoma, 72:151
in soft tissue and bone tumors, 78:115; 127
in squamous cell carcinoma, 77:60
in testicular tumors, 75:90
in therapy-related leukemia, 75:11
in Warthin tumor, 76:129
lymphoma, 72:33
malignant melanoma, 72:16, 109
Chromosome instability
chromosome 16 and familial disease, 78:160
in colorectal cancer, 73:23
in lymphocytes, 73:23
Chronic Lymphocytic Leukemia (CLL)
bcl rearrangements in B-CLL, 73:165
cytogenetic changes, 73:65
der(14) resulting in partial +12, 76:159
FISH studies in, 72:83; 78:108
interphase cytogenetics, 72:83
Richter syndrome, 73:65
trisomy 12, 72:83
t(17;21), rather than t(12;17), shows with FISH, 78:108
+12 in, 72:83
18 in, 77:39
Chronic Myelocytic Leukemia (CML)
blast crisis, 72:48; 76:151
BMT in, 73:130
complex Ph chromosomes, 78:153
cytogenetics, 72:24, 48, 65, 105; 73:57; 76:151
extramedullary blastic phase, 76:151
FISH studies in, 72:24, 105; 73:17, 130
FISH studies of complex Ph, 78:153
follow-up, 74:156
immunophenotypes, 72:48
in child, 76:151
i(17q) in, 73:17
MRD in, 73:130
Ph+, 72:24, 48, 65; 73:57; 76:151
T-cell receptors, 72:48
TCR, 72:48
telomere shortening and genetic changes, 78:64
translocations in, 72:65, 105
trisomy 8, 72:24
variant Ph in, 73:57; 74:156
Chronic Myelogenous Leukemia; see Chronic Myelocytic Leukemia
Chronic Myelomonocytic Leukemia (CMMoL); also see MDS
clinical aspects, 74:40; 75:147
cytogenetics, 74:40; 75:147
in secondary, 75:64
inv(3)(q21q26) in, 75:147
molecular studies, 74:40
ras mutations, 74:40
survival, 74:40
t(9;11)(p22;q23) in secondary, 75:64
+19 as sole change, 74:62
with normal platelet count, 75:147
Clear Cell Sarcoma (CCS)
chromosomes 22 and 8, 72:141
polysomy 8, 72:141
Colorectal tumors

adenomas, 74:105
APC gene mutations in FAP, 77:171, 186
APC mutations, 77:151
APC mutations in sporadic cancer, 77:186
clonal changes in adenomas, 77:186
cytogenetics of adenomas, 74:105
cytogenetics in cancer, 77:158
genetic heterogeneity, 77:158
genetic predisposition, 73:23; 77:151
K-*ras* mutations, 77:155
linkage studies in cancer, 77:171
lymphocyte chromosome instability, 73:23
Comparative Genomic Hybridization (CGH)
in bladder cancer, 77:149
in breast cancer, 77:149
in neuroblastoma, 77:180
in solid tumors, 77:149
Cystadenolymphoma (Warthin Tumor)
cytogenetics, 76:129
Cytogenetic changes
adenolipomas of breast, 72:146
in ALL, 72:92; 73:103; 75:117; 76:118; 77:134
in ANLL, 72:44, 73, 75, 86, 105; 77:134
in APL, 72:73, 75
in brain tumors, 73:46
in chordomas, 73:147; 75:23
in clear cell sarcoma, 72:141
in CLL, 72:83; 73:65
in CML, 72:48, 65; 105; 73:57
in colorectal adenomas, 74:104
in chondrosarcoma, 76:100
in dermatofibrosarcoma protuberans, 76:1
in endometrial cancer, 73:142
in ependymomas, 74:132
in gallbladder cancer, 76:15
in gliomas, 72:55; 73:46; 75:77; 76:85
in hemangiopericytomas, 72:137
in hibernoma, 72:59
in hidradenoma, 77:26
in lacrimal gland tumors, 75:134
in leiomyoma, 77:65
in MDS, 74:40; 77:134
in melanoma, 77:69
in multiple myeloma, 76:10; 78:210
in neuroblastoma, 74:30
in non-neoplastic solid tissues, 77:183
in osteosarcoma, 77:81
in ovarian cancer, 73:33; 77:99
in pancreatic endocrine tumors, 77:55
in phyllodes tumors of breast, 78:200
in primary MDS, 78:219
in Richter syndrome, 73:65
in salivary gland tumors, 75:137
in sarcoma, 72:151
in soft tissue and bone tumors, 78:115, 127
in squamous cell carcinoma, 77:60
in testicular tumors, 75:90
in therapy-related leukemia, 75:11
in Warthin tumor, 76:129
lymphoma, 72:33
malignant melanoma, 72:16, 109

Deletions
in chondrosarcomas, 76:100
in chordomas, 73:147
in osteosarcomas, 77:81
in ovarian cancer, 73:33
5q- in desmoid tumor, 78:94
5q- in RAEB, 74:8
7q- in various disorders, 78:181
7q22 in leiomyoma, 77:65
9q- in AML (M2), 78:239
17p, refractory disease and hematologic malignancies, 77:134
Derivative chromosomes
in chordomas, 73:147
in ovarian cancer, 73:33
Dermatofibrosarcoma Protuberans
chromosome 17 and rings, 76:1
cytogenetics, 75:156; 76:1
FISH studies in, 76:1
ring chromosomes, 76:1
t(2;17)(q33;q25), 75:156
Desmoid tumor
in Gardner syndrome, 78:94
5q- in, 78:94
Dicentric chromosomes
dic(15;17)(q11;p11) in ANLL, 72:86
in ANLL, 72:86
DNA methylation
methylcytosine-rich heterochromatin on banded chromosomes, 78:87
varying status in cells, 78:87
Double Minute Chromosomes (dmin)
in ANLL, 72:86
in osteosarcoma, 77:81
in prostate cancer, 72:157
in rhabdomyosarcoma, 76:125
Down syndrome
ANLL in, 76:72
in family with fragile 16, 78:160
inv(6) in AML, 73:157
MDS in, 73:157
t(8;21)(q22;q22) in ANLL, 76:72

Effusions
absence of -7 in normal cells, 78:78
FISH studies in, 78:78
Endometrial carcinoma
cytogenetics, 73:142; 77:197
FISH analysis, 73:142
Endometrial stromal sarcoma
chromosomes 3, 6 and 7, 77:45
karyotypic changes, 77:45
Endometriosis
cytogenetic studies, 78:172
Ependymoma and Ependymoblastoma
chromosome changes, 73:46; 74:132

sex chromosome loss, 73:46
Epithelioid sarcoma
cytogenetics, 72:151
t(8;22)(q22;q11), 72:151
Erratum
æavdar et al. 69:38-40, 1993, 72:163
Palka et al. 61:162-164, 1993, 72:81
Riske et al. 72:44-47, 1994, 76:161
Shekhter-Levin et al. 73:157-160, 1994, 76:161
Ewing sarcoma
double-target FISH, 77:202
erg gene translocation, 76:19
FISH studies, 74:13; 77:202
interphase cytogenetics, 74:13
molecular studies of t(11;22), 74:13; 76:19
+8 in, 77:202

Familial tumors and diseases
AML, 76:65
colorectal, 73:23
fragile chromosome 16, 78:160
genetic mechanisms in AML, 76:65
in families of Wilms children, 77:129
in families with renal tumors in children, 72:28; 77:129
leukemia predisposition, 76:65
retinoblastoma and fragile sites, 78:72
tumors and diseases in family with fragile 16, 78:160
Fanconi anemia
apoptosis in, 75:67
mitomycin C, 75:67
Fat tumors; see Lipoma or Adipose tissue tumors
Fibrosarcoma
cell line, 73:109
chromosome 1, 73:109
congenital, 78:82
suppressor activity on 1q, 73:109
trisomies in, 78:82
+11 in congenital, 78:82
Fibrous dysplasia
chromosome change, 77:114
t(6;11)(q15;p15) in, 77:114
FISH (fluorescence in-situ hybridization)
apoptosis detection, 77:150
bcl rearrangements in CLL, 73:165
BMT, 73:130
cosmid probes, 77:99
double target, 73:103
in acute monocytic leukemia, 74:50
in ALL, 73:103
in aneuploidy, 72:78
in ANLL, 72:86
in APL, 72:73
in archival specimens, 75:40
in bladder cancer, 73:8; 77:118
in breast cancer, 73:75; 75:1
in Burkitt lymphoma, 76:136
in cervical lesions, 75:120
in CLL, 78:108
in CML, 72:105, 73:130
in dermatofibrosarcoma protuberans, 76:1
in detection of MRD, 76:59
in endometrial cancer, 73:142
in Ewing sarcoma and neuroepithelioma, 74:13
in fibroadenoma of breast, 76:145
in fibrosarcoma, 73:109
in follicular lymphoma, 76:140
in germ cell tumors, 73:11; 73:53
in hemangioblastoma, 77:1
in leiomyoma, 74:19
in leiomyosarcoma, 74:19
in multiple myeloma, 76:10
in ovarian cancer, 74:1; 77:99
in pheochromocytoma, 77:1
in Ph- CML, 78:153
in prostate tumor, 75:40
in radiation induced chromosome change, 77:166
in renal cell tumors, 77:1
in solid tumors, 77:165, 166
interphase cytogenetics, 72:24, 86; 73:130
in trisomy 11 in AMMoL, 77:33
in tumors of von Hippel-Lindau syndrome, 77:1
in Warthin tumor, 76:129
i(17q) in leukemias, 73:17
methodological development, 77:164
MRD, 73:130
new method, 77:149
of ring chromosomes, 76:1
of -18 in lymphoid disorders, 77:39
prediction of radiosensitivity, 77:166
repetitive, 74:1
resource laboratories, 77:165
studies of complex PH, 78:153
use in differentiating translocation, 78:108
5q- chromosome, 74:8
6q and ovarian cancer, 77:99
+8 in CML, 72:24
+12 in CLL, 72:83
Fourth European Workshop on Cytogenetics and Molecular Genetics
of Human Solid Tumors
Abstracts, 77:149-204
Editorial Comment, 77:147
Fragile site(s)
at 10q23 in leiomyoma, 74:73
in retinoblastoma patients with families, 78:72
spontaneous expression in leiomyoma, 74:73

Gallbladder tumors
cytogenetics in cancer, 76:15
karyotypes, 76:15
Gardner syndrome
desmoid tumor with 5q-, 78:94
Gastric cancer
chromosome 6 in, 77:172
cytogenetics, 75:145
cytogenetics, CGH and Southern blotting in, 77:172
metastatic (pleura), 75:145
primary and metastatic, 75:45

oncogene amplifications, 77:172
p53 changes, 75:45
RB gene in, 77:172
Gene(s)
bcl in B-CLL, 73:165
bcl2 in B-cell line, 74:87
CHOP and MDM2 in sarcoma, 78:165
CHOP in MFH, 72:155
erg gene in Ewing sarcoma, 76:19
EMS1 gene at 11q13 in breast cancer, 77:171
EWS/FLI-1 gene, 77:154
h-*ras* in giant cell tumor of bone, 74:95
IL4 gene in Waldenström macroglobulinemia, 75:153
MLL-1 and RARA in M5 ANLL, 74:50
p53 in ataxia-telangiectasia cells, 77:14
p53 in cancer, 77:153
p53 in gastric cancer, 75:45
p53 in gliomas, 74:139
p53 mutations in fixed and frozen tissues, 77:167
p53 in second neoplasms, 76:148
RAG-1 in actue leukemia, 78:40
second suppressor gene in breast cancer, 76:106
tumor suppressor gene in fibrosarcoma, 73:109
Genitourinary tumors
in families with children with renal tumors, 72:28
ovarian, 73:33, 60
Genomic imprinting and imbalance
FISH, CGH, and karyotyping of imbalance, 77:163
role of, 77:151
tumorigenesis, 73:82
Genotype
and phenotype analysis by MAC, 72:1
analysis in interphase of mitotic cell, 72:1
MAC (morphology, antibody and chromosomes) analysis of interphase and mitotic cells, 72:1
Germ cell tumors
analysis of paraffin sections, 77:164
carcinoma in situ: precursor for invasive lesions, 77:194
cell fusion in, 77:195
cerebral, 74:25
chromosome translocation, 73:11
chromosome 12 anomalies, 77:160
chromosome 15, 77:152
clonality of combined tumors, 77:195
combined tumor, 77:195
cytogenetics of pediatric, 74:54
cytogenetics of teratoma, 75:90
extragonadal, 73:11, 53; 74:25, 54; 77:111
FISH studies in, 73:11, 53; 77:195; 78:145
gene expression, 77:152
gonadal, 74:54; 75:90
i(12p) in mediastinal tumor, 73:53; 77:111
i(12p) negative seminoma, 78:145
mediastinal, 77:111
molecular analysis of extragonadal tumors, 77:176
molecular studies in, 73:11
ovarian, 74:54
pediatric, 74:54; 77:196
pediatric tumors: chromosome changes, 77:196
refractory anemia with excess blasts, 77:111
testicular, 74:54; 75:90
XXY karyotype in cerebral, 74:25
YAC, cosmid and other probes, 77:195
12p11.2-p12.1 region, 78:145
Giant cell tumor
H-*ras* locus in, 74:95
molecular studies in, 74:95
of bone, 74:95
Glioblastoma
chromosome changes, 73:46; 75:77; 76:85
chromosome painting, 77:181
LOH in, 74:139
microsatellite analysis, 74:139
molecular studies, 74:139
p53 mutation, 74:139
recurrent, 76:85
ros oncogene in, 72:130
sex chromosome loss, 73:46
7p, 9q and 12q in, 77:181
Glioma(s)
chromosome 7, 72:55
chromosomes 7, 9, 10, 13, 17 and 22, 73:122
cytogenetics, 72:55; 73:46; 75:77; 76:85
DNA amplification, 77:156
LOH in, 74:139
microsatellite analysis, 74:139
molecular studies in, 72:55, 130; 73:122; 74:139
oncogenes in, 72:130
p53 change in low-grade, 78:68
p53 mutations, 74:139
RFLP analysis, 72:55
recurrent cytogenetics, 76:85
ros oncogene in, 72:130
sex chromosome loss, 73:46; 75:77
Granulocytic sarcoma
cytogenetics, 74:59
t(12;22)(p11;q11) in, 74:59
t(X;1)(q28;q22) in, 74:59
Granulomatous Slack Skin (GSS)
cytogenetics of, 72:95
molecular studies, 72:95

Head and Neck
cytogenetics of carcinoma, 77:60, 188
EMS1 gene at 11q13 in cancer, 77:171
non-squamous cancers, 77:188
squamous cell carcinoma 77:60
Hemangioblastoma
cerebellar, 77;1
cytogenetics of, 77:1
in von Hippel-Lindau syndrome, 77:1
Hemangiopericytoma
cytogenetics of, 72:137
translocations in, 72:137
Hibernoma
cytogenetic changes, 72:59
10q22 and 11q13 in, 72:59
Hidradenoma

chromosome changes in, 77:26
clear cell, 77:26
cytogenetic heterogeneity, 77:26
skin, 77:26
Hypodiploidy
in AML, 74:147-148
in M2 ANLL, 74:147
Hypomethylation
in ALL, 78:40
in ANLL, 78:40
TCR-β, 78:40

Immunoglobulins
in CD7+ AML, 73:69
in CML, 72:48
in lymphoma, 72:33
Insertion
in renal cell carcinoma, 77:1
ins(10;5)(p13;q31q13) in ovarian cancer, 77:89
In-Situ Hybridization
double target, 73:103; 77:165
FISH analysis, 72:24, 83; 73:8, 11, 17
in ALL, 73:103
in breast cancer, 73:75; 75:1
in cell analysis, 72:1
in embedded sections, 73:134
in endometrial cancer, 73:142
in Ewing sarcoma and neuroepithelioma, 74:13
in fibrosarcoma, 73:109
in germ cell tumors, 73:11, 53
in leiomyoma, 74:19
in leiomyosarcoma, 74:19
in synovial sarcoma, 73:89
in tumors of von Hippel-Lindau syndrome, 77:1
in 5q- chromosome, 74:8
i(17q) in leukemia, 73:17
MAC technique, 72:1
Insulinoma
cytogenetics, 77:189
Interphase studies
bcl in CLL, 73:165
BMT, 73:130
cytogenetics, 73:134
double target, 73:103; 77:165
FISH analysis, 72:24, 73, 83, 86; 73:8, 17, 103, 130
in ALL, 73:103
in bladder cancer, 73:8
in breast cancer, 73:75; 75:1
in CML, 72:105, 73:17
in endometrial cancer, 73:142
in Ewing sarcoma and neuroepithelioma, 74:13
in fibrosarcoma, 73:109
in germ cell tumors, 73:11, 53
in leiomyoma, 74:19
in leiomyosarcoma, 74:19
in ovarian cancer, 74:1
in paraffin-embedded sections, 73:134
in synovial sarcoma, 73:89
in tumors of von Hippel-Lindau syndrome, 77:1
in Warthin tumors, 76:129
i(17q) in leukemia, 73:17
MRD, 73:130
of +11 in AMMoL, 77:33
5q- chromosome, 74:8
Inversion(s)
chromosome 6 (pericentric) in AML, 73:157
in childhood ALL, 72:92
in hidradenoma, 77:26
in T-cell leukemia, 72:92
inv(2) in rhabdomyosarcoma, 78:214
inv(12) in lymphoma, 77:74
inv(14)(q11q32) in T-ALL, 72:92
inv(X) in hemangiopericytoma, 72:137
of chromosome 3 in CMMoL, 75:147
Isochromosome
FISH studies of i(17q), 73:17
i(1q) in endometrial cancer, 73:142
i(1q) in uveal melanoma, 72:109
i(5p) in cervical cancer, 76:56
i(6p) in lymphoma, 77:74
i(8q) in B-ALL, 73:84
i(8q) in uveal melanoma, 72:109
i(12p) in germ cell tumors, 73:53; 75:90; 77:111
i(17q) in leukemia, 73:17

Karyotypic changes
adenolipomas of breast, 72:146
in ALL, 72:92; 73:103; 75:117; 76:118; 77:134
in ANLL, 72:44, 73, 75, 86, 105; 77:134
in APL, 72:73, 75
in brain tumors, 73:46
in chordomas, 73:147; 75:23
in clear cell sarcoma, 72:141
in CLL, 72:83; 73:65
in CML, 72:48, 65; 105; 73:57
in colorectal adenomas, 74:104
in chondrosarcoma, 76:100
in dermatofibrosarcoma protuberans, 76:1
in endometrial cancer, 73:142
in ependymomas, 74:132
in gallbladder cancer, 76:15
in gliomas, 72:55; 73:46; 75:77; 76:85
in hemangiopericytomas, 72:137
in hibernoma, 72:59
in hidradenoma, 77:26
in lacrimal gland tumors, 75:134
in leiomyoma, 77:65
in MDS, 74:40; 77:134
in melanoma, 77:69
in multiple myeloma, 76:10; 78:210
in neuroblastoma, 74:30
in non-neoplastic solid tissues, 77:183
in osteosarcoma, 77:81
in ovarian cancer, 73:33; 77:99
in pancreatic endocrine tumors, 77:55
in phyllodes tumors of breast, 78:200
in primary MDS, 78:219
in Richter syndrome, 73:65

in salivary gland tumors, 75:137
in sarcoma, 72:151
in squamous cell carcinoma, 77:60
in testicular tumors, 75:90
in therapy-related leukemia, 75:11
in Warthin tumor, 76:129
lymphoma, 72:33
malignant melanoma, 72:16, 109
Kidney tumors; also see Renal tumors
cytogenetics of leiomyosarcoma, 72:126
cortical, 73:134
flow cytometric DNA, 73:134
interphase cytogenetics, 73:134
leiomyosarcoma, 72:126

Lacrimal gland tumors
chromosome 3, 8, 9 and 12, 75:133
comparison with salivary gland, 78:133
cytogenetics, 75:133
Leiomyoma
archival tissue cytogenetics, 74:19
cell line, 77:203
chromosome changes, 74:19; 77:65
c-*met* loss, 77:203
cytogenetics vs. leiomyosarcoma, 74:19
FISH studies, 74:19
fragile site at 10q23, 74:73
mapping of 12q breakpoint, 77:201
translocations in, 77:65
7q- in, 77:203
7q22 in, 77:65
Leiomyosarcoma
archival tissue cytogenetics, 74:19
chromosome changes, 74:19
cytogenetics vs. leiomyoma, 74:19
FISH studies, 74:19
kidney, 72:126
Lipoblastoma
diagnostic implications of 8q, 76:39
translocation t(8;14) in, 76:39
8q in, 76:39; 78:232
8q11-13 in, 78:232
Lipomas
adenolipomas of breast, 72:146
cytogenetics of, 72:146
of breast, 72:146
t(11;12) in lipoma, 77:162
12q13-15 in atypical, 77:161
Liposarcoma
CGH in, 77:200
c-*myc*, 76:47
TLS-CHOP fusion variants, 77:177
TLS/FUS and EWS genes, 77:155
TP53 mutations in, 76:46
t(12;16)(q13;p11) in, 77:177
12q13-15 region, 77:161
Liver tumors
molecular studies, 77:154
Loss of heterozygosity (LOH)
in malignant gliomas, 74:139
in ovarian tumors, 77:150
microsatellite analysis, 74:139
p53 mutations, 74:139
Lung tumors
chromosome changes in non-small cell cancers, 77:186
c-*myc* and related genes, 77:173, 187
cytogenetics of adenocarcinomas, 77:186
deletions in SCLC, 77:188
FISH and cytogenetics in small cell cancer, 77:187
FISH in lung brushes, 77:164
gene amplification (c-*myc*), 77:155
GST-pi expression, 77:173
isochromosomes in, 74:120
multistep carcinogenesis, 77:159
origin of isochromosomes, 74:120
p53 in cancer, 77:173
3p21 in SCLC, 77:187
9p- changes, 77:186
11q13, EMS-1 and CCND1 genes, 77:173
Lymphocytes
chromosome changes in male patient with breast cancer, 78:99
chromosome instability, 73:23
colorectal cancer and chromosome instability, 73:23
Lymphoma
B-cell, 72:33
brain, 73:46
Burkitt, 76:136
chromosome changes, 72:33, 76:136, 140; 77:75, 91; 78:15
chromosome 11 changes, 78:36
diffuse large cell, 77:91
follicular, 76:140
immunoglobulin gene loci, 72:33
karyotypes in MALT lymphoma, 77:76
MALT lymphoma, 77:74
mucosa-associated, 77:74
Sézary syndrome, 75:130
T-cell, peripheral, 78:15
t(1;21)(q21;p11) in diffuse large cell, 77:91
t(14;18) and chromosome 11, 78:36
t(14;19)(q32;q13) in follicular, 75:72
3q27 involvement, 72:33
9q in follicular, 76:140
+12 in mucosa-associated, 77:74
-18 in, 77:39

MAC methodology
analysis of genotype and phenotype, 72:1
morphology, antibody and chromosomes, 72:1
Malignant Fibrous Histiocytoma (MFH)
c-*myc* in, 76:47
molecular studies in, 72:155
no rearrangement of CHOP, 72:155
TP53 mutations in, 76:47
Mastocytosis
systemic, 78:236
t(X;8) in, 78:236

Mediastinal
cytogenetic findings in tumors, 73:55
FISH studies in germ cell tumor, 73:53
germ cell tumor, 73:53
Medulloblastoma
FISH studies, 77:181, 182; 78:1
i(17q) in, 77:181; 78:1
Megakaryoblastic leukemia (M7)
cytogenetic findings in, 74:66
+21 in, 74:66
Melanoma, Malignant
brain metastasis, 72:16
chromosome changes, 72:16, 109; 77:69, 144, 182
chromosome 6, 77:182
chromosomes 1, 3, 6 and 9, 77:69
chromosomes 6, 8 and 9 in uveal, 72:109
clinical correlations in uveal, 72:109
FISH in, 77:182
LOH of chromosome 3 in uveal, 77:183
marker chromosomes, 77:182
ocular, 77:182
t(1;14) in cell lines, 77:183
uveal, 72:109; 77:144
Meningioma
chromosome changes, 73:46; 77:179, 78:46
histology and cytogenetics, 78:46
MGCR in, 77:179
NF-2 gene in, 77:178
sex chromosome loss, 73:46
tumor suppressor gene, 77:174
value of chromosome analysis, 77:179
Merkel Cell Carcinoma
cytogenetics, 75:74
translocations in, 75:74
Mesothelioma
cell line, 77:203
WT-1 gene in, 77:203
Methodology
choice in solid tumor cytogenetics, 76:77
cytochemistry, 72:1
FISH, 72:24
high-quality banding in blood disorders, 74:109
immunochemistry, 72:1
in paraffin-embedded sections, 73:134
in-situ hybridization, 72:1
interphase cytogenetics, 73:134
MAC (morphology, antibody and chromosomes) technique, 72:1
scanning force microscopy, 76:93
solid tumor cytogenetics, 72:161
Minimal Residual Disease (MRD)
BMT, 73:130
detection by FISH, 73:130, 76:59
FISH and, 73:130; 76:59
in CML, 73:130, 76:59
probes for t(9;22), X and Y, 73:130
Models
cytogenetics, 76:77
in solid tumors, 76:77
methodological choices, 76:77
Molecular studies
c-*myc* and TP53 in sarcoma, 76:47
in acute monocytic leukemia, 74:50
in ALL, 73:103
in ALL cell line, 75:31
in B-cell line, 74:87
in B-CLL, 73:165
in BMT and MRD, 73:130
in breast cancer, 75:1; 76:106
in breast cancer cell lines, 76:23; 77:19
in CD7+ AML, 73:69
in CML, 72:48, 65
in Ewing sarcoma, 76:19
in Ewing sarcoma and neuroepithelioma, 74:13
in Fanconi anemia, 75:67
in fibrosarcoma, 73:109
in gastric cancer, 75:45
in germ cell tumors, 73:11; 78:145
in giant cell tumor of bone, 74:95
in gliomas, 72:55, 130; 73:122; 74:139
in irradiated ataxia-telangiectasia cells, 77:14
in MDS, 74:40
in MFH, 72:155
in ovarian tumors, 73:60
in synovial sarcoma, 73:89
in Syrian hamster cell line, 75:51
in trophoblastic tumors, 73:95
in von Hippel-Lindau syndrome, 77:1
in Waldenström macroglobulinemia, 75:153
in 5q- chromosome, 74:8
of CHOP protooncogene, 78:165
of soft tissue sarcomas, 77:200
p53 in patients with secondary tumors, 76:148
second gene in breast cancer, 76:106
studies in Wilms tumor, 77:93
TCR in CML, 72:48
Monosomy
FISH studies of -18, 77:39
9 in bladder cancer, 77:118
-18 in lymphoid malignancies, 77:39
22 and NM23H1 gene, 77:177
Mucoepidermoid carcinoma; see Carcinoma
Multiple Endocrine Neoplasia (Type 2)
Hirschsprung disease and, 77:158
receptor gene in, 77:158
ret mutation in, 77:175
Multiple Myeloma
chromosome painting, 76:10
clinical parameters, 78:210
cytogenetics, 74:115; 76:10; 78:210
DNA content, 74:115
image analysis, 74:115
t(1;16)(p11;p11), 76:10
Myelodysplasia; see Myelodysplastic syndromes
Myelodysplastic Syndromes (MDS)
BMT in, 72:68
clinical aspects, 74:40; 78:219
CMMoL, 74:40
cytogenetics, 72:68; 74:40; 78:219
germ cell tumor and, 77:111

in secondary CMMoL, 75:64
inv(6) in child with Down syndrome, 73:157
molecular studies, 74:40
primary: cytogenetics, 78:219
RA, 74:40
RAEB, 74:40; 77:111
RAEB-T, 74:40
RARS, 74:40
ras mutations, 74:40
survival, 74:40; 78:219
therapy-related in children, 75:11
treatment related, 76:50
t(1;7)-unbalanced in AML, 74:35
t(1;7)(p26;q32) in primary, 75:103
t(3;21)(q26;q22) in, 76:50
5q- in RAEB, 74:8
+19 as sole change, 74:62
Myeloproliferative Disorders (MPD)
chromosome 8 in, 75:106
cytogenetics in children, 75:11
leukemic transformation, 76:50
progression, 75:106; 76:50
refractory disease, 77:134
therapy-related, 75:11
t(3;21)(q26;q22), 76:50
t(8;21)(q22;q22), 75:106
17p monosomy and refractory disease, 77:134
Myositis
cell culture, 76:157
proliferative, 76:157
+2 in, 76:157

Neoplasms; see Tumors
Nephroma
congenital, 77:50
FISH studies, 77:50
histological subtype and +11, 77:50
mesoblastic, 77:50
+11 in, 77:50
Neuroblastoma
cell behavior and growth, 77:156
CGH in, 77:180
cytogenetic changes, 74:30
genetics in children, 77:179
lack of p53 mutations, 77:180
N-*myc* in, 77:175, 179
t(1;17), 77:156, 157
1p deletions, 77:157
1p36 and translocations in, 77:174
Neuroectodermal tumors
oncogene, 77:156
22q12 in, 77:156
Neurofibromatosis
gene in Schwannomas, 77:178
gene in type 2, 77:174
mutations in, 77:174
Neurofibrosarcoma
c-*myc* in, 76:47
TP53 mutations in, 76:47
Nodular Fasciitis
chromosome changes, 76:154
t(3;15)(q21;q22) in, 76:154
Non-Hodgkin Lymphoma; see Lymphoma

Oligodendroblastoma
chromosome changes, 73:46; 75:77; 76:85
molecular studies, 73:122
recurrent, 76:85
Oncogene(s)
c-*myb* in ALL cell line, 75:31
c-*myc* amplification, 76:47
c-*myc* in sarcoma, 76:47
CHOP/GADD153 in sarcomas, 78:165
expression in gliomas, 72:130
in Syrian hamster cells, 75:51
oncogene activation, 75:51
papilloma virus and p53, 77:178
PDGF in ovarian tumors, 73:60
ras in MDS, 74:40
ros in gliomas, 72:130
v-*src* in marmoset cells, 74:123
Oral tumors
cytogenetics of squamous cell carcinoma, 77:188, 189
Osteosarcoma
c-*myc* in, 76:47
cytogenetics, 77:81
deletions, rings and dmin, 77:81
extraskeletal, 76:47
lack of *ras* mutations, 77:177
TP53 mutations, 76:47
Ovarian cancer
breast-ovarian cancer gene, 77:154
cell lines, 77:197
CGH in, 77:163
chromosome changes, 73:33; 74:1; 77:89, 99, 197
chromosome 6 in, 77:99
clonal changes in, 73:33; 74:1
FISH studies, 74:1; 77:99
GTG-banding, 74:1
ins(10;5)(p13;q31q13) in small cell cancer, 77:89
molecular studies in epithelial tumors, 73:60
PDGF expression, 73:60
small cell, 77:89
-X in, 73:33
yolk sac tumor, 77:197, 198
1p- in yolk sac tumor, 77:197
6q26-27 study in cancer, 77:164
+7 in, 73:33

Pancreas
cell line, 76:29
chromosomes in endocrine neoplasms, 77:55
cytogenetics in cancers, 77:190
cytogenetics of tumors and cell line, 76:29
endocrine neoplasms, 77:55
metastasis of cancer, 76:29
periampullary adenocarcinoma, 76:29
Paraganglioma
allelic imbalance, 77:168

PCR
in situ hybridization, 77:167
visualization of chromosomal subregions, 77:167
Peripheral nerve sheath tumors
cytogenetics, 78:138
malignant, 78:138
Peripheral neuroepithelioma
FISH studies, 74:13
interphase cytogenetics, 74:13
molecular studies, 74:13
Phenotype
analysis of interphase and mitotic cells, 72:1
and genotype analysis by MAC, 72:1
MAC (morphology, antibody and chromosomes) analysis of interphase and mitotic cells, 72:1
Pheochromocytoma
cytogenetics, 77:1
in von Hippel-Lindau syndrome, 77:1
Philadelphia (Ph) chromosome
FISH studies of, 73:130; 78:153
follow-up, 74:156
in ALL, 76:70
in CML, 72:24, 48, 65; 73:57; 74:156; 78:153
in Ph- CML, 78:153
Southern blot analysis, 72:65
variant, 73:57; 74:156; 78:153
Phyllodes tumors; see Breast tumors
Plasma cell
chromosomal changes in leukemia, 76:36
leukemia, 76:36
MAC studies in leukemia, 76:36
Pleural fluid; see Effusions
Porokeratosis
cell cultures, 73:161
chromosomes after X-ray, 73:161
fibroblasts, 73:161
Prolymphocytic leukemia
karyotypic changes, 78:28
T-cell, 78:28
Protooncogenes; see Oncogenes
Prostate
adenocarcinoma, 72:157
CGH in cancer, 77:163
double minutes in, 72:157
FISH studies in, 75:40
numerical chromosome change, 77:159
PIN: cytogenetic study, 77:194

Receptors
in CD7+ AML, 73:69
T-cell in GSS, 72:95
Rectal tumor; see Colorectal tumors
Refractory Anemia (RA); also see MDS
clinical aspects, 74:40
cytogenetics, 74:40
molecular studies, 74:40
ras mutations, 74:40
survival, 74:40
+19 as sole change, 74:62
Refractory Anemia with Excess Blasts
clinical aspects, 74:40
cytogenetics, 74:40; 77:111
FISH studies, 78:7
germ cell tumor and, 77:111
interstitial breaks in 5q, 74:8
i(12p) in mediastinal germ-cell tumor, 77:111
molecular studies, 74:40
ras mutations, 74:40
survival, 74:40
t(1;7)(p36;q32) in, 75:103
t(1;17)(q11;p11), 78:7
5q-, 74:8
+19 as sole change, 74:62
Refractory Anemia with Excess Blasts in Transformation (RAEB-T); also see MDS
clinical aspects, 74:40
cytogenetics, 74:40
molecular studies, 74:40
ras mutations, 74:40
survival, 74:40
+19 as sole change, 74:62
Refractory Anemia with Ring Sideroblasts (RARS); also see MDS
clinical aspects, 74:40
cytogenetics, 74:40
molecular studies, 74:40
ras mutations, 74:40
survival, 74:40
+19 as sole change, 74:62
Renal tumors
chromoprobe carcinoma, 77:192
chromosome 3 mapping, 77:191
chromosome 7 in Wilms tumor, 77:93
clinical correlates and pathologic, 77:193
cortical, 73:134
cytogenetic model, 77:160
cytogenetics of, 77:1; 191
cytogenetics of cell line, 78:175
cytogenetics of oncocytomas, 77:192
deletion mapping of chromosomes 14, 8, 17 and 18, 77:191
FISH studies in, 77:1
flow cytometric DNA, 73:134
growth factor gene, 78:175
hereditary papillary cancer, 77:192
in children, 72:28
interphase cytogenetics, 73:134; 77:1
in von Hippel-Lindau syndrome, 77:1
i(12p) in a testicular metastasis of a renal cancer, 77:192
mesoblastic nephroma, 77:50
microsatellite markers, 77:191
papillary cancers, 77:193
tumors in families with children with renal tumors, 72:28
t(3;8) and t(3;6) in familial cancer, 77:176
Wilms tumor, 77:93
YAC spanning breakpoint in t(X;1), 77:176
+11 in nephroma, 77:50

11q13 in oncocytoma, 77:160
Retinoblastoma
cytogenetics in, 76:112
fragile sites in patients with families, 78:72
phenotype variants, 76:112
6p in, 76:112
6p+ in, 76:112
Rhabdoid tumor
childhood, 77:202
t(9;22)(p34;q12-13) in, 77:202
Rhabdomyosarcoma
alveolar, 78:214
chromosomal differences in embryonal vs. alveolar, 77:201
c-*myc* in, 76:47
cytogenetics, 76:125; 77:201; 78:214
dmin in, 76:125
embryonal, 77:201
inv(2)(p15q35) in alveolar, 78:214
TP53 mutations, 76:47
1p in embryonal, 77:201
Richter syndrome
chromosome changes in, 73:67
cytogenetics, 73:65
Ring chromosome
in dermatofibrosarcoma protuberans, 76:1
in fibroadenoma of breast, 76:145
in hidradenoma, 77:26
in osteosarcoma, 77:81
in uveal melanoma, 72:109

Salivary gland tumors
comparison with lacrimal gland, 75:133
cytogenetics, 75:133; 76:96
+5 in gland, 76:96
Sarcoma
CHOP oncogene in, 78:165
c-*myc* in, 76:47
chondrosarcoma, 76:100
clear cell (CCS), 72:141
cytogenetic heterogeneity, 78:127
dermatofibrosarcoma protuberans, 75:156
epithelioid, 72:151
Ewing, 74:13; 76:19
fibrosarcoma, 73:109
granulocytic, 74:59
leiomyosarcoma of kidney, 72:126
rhabdomyosarcoma, 76:125
soft tissue, 78:138
soft tissue sarcomas: molecular studies, 77:200
synovial, 73:89
TP53 mutations, 76:47
12q13-14 amplica, 77:200
Schwannoma
NF-2 gene in, 77:178
vestibular, 77:178
Secondary leukemia
in APL, 74:84
in children, 75:11
t(3;21)(q26;q22) in, 74:84
11p15 and 3q21q26 in therapy-related leukemia in children, 75:11
Sex chromosomes
changes in tumors, 72:160
loss in brain tumors, 73:46; 75:77
Sézary syndrome
cytogenetic studies, 75:130
translocations in, 75:130
Sigmoid tumors; see Colorectal tumors
Skin
der(17;22)(q10;q10) in metastatic carcinoma, 74:153
granulomatous slack skin (GSS), 72:95
hidradenoma, 77:26
molecular analysis in GSS, 72:95
Soft tissue tumors
cytogenetic heterogeneity, 78:127
cytogenetics of tumors, 78:115, 127
intratumor heterogeneity, 78:127
sarcoma, 78:138
Solid tumors
cytogenetics of soft tissue and bone, 78:115
improved procedure for chromosome preparations, 72:161
+5 in marrow cultures from patients, 78:207
Squamous cell carcinoma
chromosomes 1, 6, 12 and 3, 77:60
cytogenetics, 77:60
head and neck, 77:60
Stomach cancer; see Gastric cancer
Survival
factors in ANLL, 73:1
long in ANLL, 73:1
Synovial sarcoma
FISH studies, 73:89
histology and breakpoints, 73:89
loci on X chromosomes, 77:199
two distinct loci on X, 77:199
t(X;18) breakpoint, 77:161
t(X;18;5;4) in, 77:199
Xp11.2 breakpoint, 73:89; 77:161

T-cell lymphoma
chromosome changes, 78:15
peripheral, 78:15
Technique; see Methodology
Telomere
association, 76:33
in astrocytoma, 76:33
length in breast cancer cell line, 77:19
shortening in leukemic cells, 78:64
telomeres and genetic alterations in leukemic cells, 78:64
Testicular tumors
amplification of 12p11.2-p12.1, 78:145
cultures, 75:90
cytogenetics, 74:54; 75:90; 78:145
FISH studies in, 78:145
gene expression, 77:152

i(12p) in, 75:90; 78:145
i(12p)-negative seminoma, 78:145
molecular studies in, 78:145
seminoma, 78:145
teratomas, 75:90
Tetrasomy
chromosome 8 in ANLL, 72:101
chromosome 8 in CCS, 72:141
chromosome 8 in MDS, 72:101
Thyroid tumors
adenoma (atypical) with biclonal changes, 78:102
chromosome changes in hyperplasia, 77:190
chromosomes in, 77:190
chromosomes 1 and 10, 77:175
chromosomes 7 and 12 in benign lesions, 77:190
cytogenetics of medullary cancers, 77:178
FISH studies, 77:190
multiphasic differentiation, 78:102
p53 mutations in dog tumors, 77:169
ret mutations in medullary cancer, 77:175
trk/*ret* in papillary cancer, 77:175
Translocations
complex in CML, 78:153
in extragonadal germ cell tumors, 73:11
"jumping" 9q in follicular lymphoma, 76:140
translocations in ANLL-M2, 75:139
translocations in secondary (treatment-related) leukemias and MDS, 75:15
t(1;1)(p36;q11) in gallbladder cancer, 76:15
t(1;2)(p31;p25) in glioma, 76:88
t(1;2;9;10)(q32.2;p12q24;q12;q25) in glioma, 76:88
t(1;3)(p10;q10) in glioma, 75:77
t(1;3)(p31;p25) in glioma, 76:88
t(1;3)(p32;q21) in squamous cell carcinoma of the head and neck, 77:62
t(1;3)(p36.3;q25) in glioma, 75:77
t(1;3)(q10;q10) in pancreatic cancer (metastatic), 76:29
t(1;3)(q21;p13) in ovarian cancer, 73:33
t(1;3)(q42;p12) in ovarian cancer, 73:33
t(1;4;7)(p32;p13q32;p22q11) in glioma, 76:88
t(1;4)(q21;p16) in chondrosarcoma, 76:104
t(1;4)(q21.1;p16) in glioma, 76:88
t(1;4)(q21;q21) in phyllodes of breast, 78:200
t(1;4;11)(q31;p16;q13.1) in Sézary syndrome, 75:130
t(1;5)(p31;q32 or q33) in glioma, 76:88
t(1;5)(p36;q33) in sacral chordoma, 73:147
t(1;5)(q41;q32) in glioma, 76:89
t(1;5)(q42;p14) in glioma, 76:88
t(1;5)(q44;q14) in glioma, 76:88
t(1;6)(p22;q22) in uveal melanoma, 72:109
t(1;6)(p34;p22) in phyllodes of breast, 78:200
t(1;6)(q44;q11) in sacral chordoma, 73:147
t(1;7)(p11;p11) in myeloid leukemia, 75:16
t(1;7)(p12;p11) in ovarian cancer, 73:33
t(1;7)(p36;q32) in primary MDS, 75:103
t(1;7)(q10;p10) in MDS following AML, 74:35
t(1;7)(q11;q31) in squamous cell carcinoma of the head and neck, 77:62
t(1;7)(q12;p11) in endometrial cancer, 73:142
t(1;7)(q32;q32-34) in ANLL-M4 (secondary), 75:17
t(1;7)(q42;p15) in Wilms tumor, 77:93
t(1;7)(q42;q22) in leiomyoma, 77:65
t(1;8)(p13;q12) in Warthin tumor, 76:129
t(1;8)(p34;p23.3) in glioma, 76:89
t(1;8)(p34;q24) in phyllodes of breast, 78:200
t(1;8)(q21;q23) in sacral chordoma, 73:147
t(1;8;16)(q25;q23;q22-23) in breast fibroadenoma, 77:125
t(1;8;21)(p13;q22;q22) in ANLL-M2, 75:140
t(1;8;21)(p36;q22;q22) in ANLL-M2, 75:140
t(1;9)(q10;q10) in glioma, 75:77
t(1;9)(q11;p13) in ovarian cancer, 73:33
t(1;9;22)(q22;q34;q11) in CML, 73:57
t(1;9)(q24;p24) in salivary gland tumor, 75:137
t(1;10)(q11;p11) in squamous cell carcinoma of the head and neck, 77:62
t(1;11)(p32;q23) in ANLL-M1 (secondary), 75:15
t(1;11)(p36;q13) in ovarian cancer, 73:33
t(1;11)(q32;q23) in RAEB-t, 75:17
t(1;12)(p34;q24.32) in glioma, 76:89
t(1;12)(p36;q13) in chondrosarcoma, 76:104
t(1;12)(p36.1;q13) in ANLL-M2, 75:17
t(1;12)(q22;q24) in ovarian cancer, 73:33
t(1;12)(q32;q14) in leiomyoma, 77:65
t(1;13;19)(q12;q13;q12) in glioma, 76:88
t(1;13)(q31;q22) in glioma, 76:89
t(1;14)(p12;q12) in glioma, 76:88
t(1;14)(p22;q11.2) in malignant melanoma, 77:70
t(1;14)(p35;q21) in glioma, 76:89
t(1;14)(q21;p11) in phyllodes of breast, 78:200
t(1;15)(q12;p13) in Merkel cell carcinoma, 75:74
t(1;15)(q21;p11) in chondrosarcoma, 76:104
t(1;15)(q32;q22) in gallbladder cancer, 76:15
t(1;16)(p11;p11) in multiple myeloma, 76:10
t(1;16;21)(p32;q13;p11) in glioma, 76:88
t(1;16)(q10;p10) in breast cancer, 75:158
t(1;16)(q10;q10) in glioma, 76:88
t(1;16)(q21;q24) in ovarian cancer, 73:33
t(1;17)(q11;p11) in RAEB, 78:7
t(1;17)(q21;q23) in squamous cell carcinoma of the head and neck, 77:62
t(1;17)(q25;q21) in varicose vein, 75;27
t(1;18)(p13;q23) in Warthin tumor, 76:129
t(1;19)(p10;p10) in glioma, 75:77
t(1;19)(p13;q11) in MDS, 74:45
t(1;19)(q12;p13) in chondrosarcoma, 76:100
t(1;19)(q12;p13.3) in ALL (L1), 78:23
t(1;19)(q21;q13) in osteosarcoma, 77:83
t(1;19)(q23;p13) in ALL, 76:120
t(1;19)(q23;p13) in ANLL (M4), 73:86
t(1;20)(p22;p13) in glioma, 76:88
t(1;21)(p11;q11) in sacral chordoma, 73:147
t(1;21)(p36;q11) in ANLL-M2, 75:140
t(1;21)(p36;q11) in MDS, 75:17
t(1;21)(q11;p11) in cerebral germ cell tumor, 74:25
t(1;21)(q21;p11) in lymphoma, 77:91
t(1;21;8)(q32;q22;q22) in ANLL-M2, 75:140
t(2;5)(p23;q35) in T-lymphoma, 78:15

t(2;5;?)(p25;q14;?) in Richter syndrome, 73:65
t(2;5)(q32.1;q14) in glioma, 76:88
t(2;6)(q32;q26) in glioma, 76:88
t(2;7)(q13;p21) in glioma, 76:89
t(2;8)(p11;q24) in Burkitt lymphoma, 76:136
t(2;8)(q12;q22.3) in glioma, 76:88
t(2;8)(q33;p23) in lymphoma, 77:74
t(2;9)(p12;p23) in ALL, 76:120
t(2;9)(q23;q22) in hidradenoma, 77:26
t(2;9)(q37;q21.3) in glioma, 76:89
t(2;10)(q24;q25) in glioma, 76:88
t(2;11)(p24;q12) in glioma, 76:89
t(2;11)(q22;p15.2) in glioma, 76:88
t(2;11)(q31;p15) in MDS, 74:45
t(2;11)(q32;q11) in Waldenström macroglobulinemia, 73:169
t(2;11)(q37;q14) in glioma, 76:88
t(2;11)(q37;q23) in ANLL-M4, 75:17
t(2;12)(p13;q24.1) in hemangiopericytoma, 72:137
t(2;13)(p12;q33) in glioma, 76:88
t(2;13)(p13;p11) in osteosarcoma, 77:83
t(2;13)(p23;q11) in glioma, 76:88
t(2;13)(q31;q12) in myeloid leukemia (secondary), 75:16
t(2;13)(q32;p12) in chondrosarcoma, 76:104
t(2;13)(q32;q31) in glioma, 76:89
t(2;14)(p24;q12) in glioma, 76:88
t(2;16)(q24;p13.2) in glioma, 76:88
t(2;17)(q33;q25) in dermatofibrosarcoma protuberans, 75:156
t(2;18)(q21;q21) in sigmoid adenoma, 74:104
t(2;20)(q21;q13) in sacral chordoma, 73:147
t(2;21;8)(p25;q22;q22) in ANLL-M2, 75:140
t(2;22)(q13 or q14.1;q11.2 or q12) in glioma, 76:88
t(3;3)(q21;q26.2) in MDS, 74:45
t(3;3)(q23;q29) in RAEB (secondary), 75:15
t(3;5)(p22;q14) in malignant melanoma, 77:70
t(3;5)(q27;q22) in Ph+ CML, 73:57
t(3;6)(p21;p21) in sacral chordoma, 73:147
t(3;6)(p21;q15) in pancreatic cancer (metastatic), 76:29
t(3;6)(p25;p25) in hidradenoma, 77:26
t(3;6)(q29;p12) in ovarian cancer, 73:33
t(3;7)(p14;p21) in ovarian cancer, 73:33
t(3;7)(p22;q21) in glioma, 76:89
t(3;7)(q13;p21) in ovarian cancer, 73:33
t(3;7;5)(q13;p14q22;q32) in glioma, 76:88
t(3;8)(p21;p21) in ANLL-M4 (secondary), 75:16
t(3;8)(p21;q12) in salivary gland tumor, 75:137
t(3;8)(p21;q22) in lacrimal gland tumor, 75:134
t(3;8)(q21;q24) in ovarian cancer, 73:33
t(3;8)(q27;p12) in ovarian cancer, 73:33
t(3;9;22)(p21;q34;q11) in CML, 73:57
t(3;10)(p25;q22) in glioma, 76:88
t(3;10)(q12;q25) in glioma, 76:88
t(3;11)(p25;q23) in AML-M2, 74:35
t(3;11)(q25;q23) in ANLL-M4, 75:16
t(3;13)(p11;p11) in glioma, 75:77
t(3;14)(p21;q24) in sacral chordoma, 73:147
t(3;14)(q13;q24.2) in glioma, 76:88
t(3;14)(q21;q24) in sacral chordoma, 73:147
t(3;14)(q21;q32) in ALL, 76:120
t(3;14)(q27;q32) in lymphoma, 72:33
t(3;15)(q21;q22) in nodular fasciitis, 76:154
t(3;16)(p21.2;q21) in sigmoid adenoma, 74:104
t(3;17)(p11;q25) in ANLL-M4 (secondary), 75:15
t(3;17)(p21;p13) in varicose vein, 75:27
t(3;17)(q29;q21) in phyllodes of breast, 78:200
t(3;18)(p24;q12.3) in glioma, 76:88
t(3;19)(q13;p13.3) in pheochromocytoma, 77:1
t(3;21)(q26;q22) in secondary leukemia, 74:84
t(3;21)(q26;q22) in therapy-related MDS, 76:50
t(3;21)(q27;q22) in MDS, 74:45
t(3;22)(p26;q11) in glioma, 76:88
t(3;22)(q27;q11) in lymphoma, 72:33
t(4;5)(p14;q11) in chondrosarcoma, 76:104
t(4;5)(p15;q21) in glioma, 76:88
t(4;7)(q22;q31) in glioma, 76:89
t(4;7)(q23;q34) in myeloid leukemia (secondary), 75:16
t(4;7)(q25;q34) in ANLL-M2 (secondary), 75:15
t(4;9)(q35;q12) in osteosarcoma, 77:83
t(4;11)(q21;q23) in ALL, 76:120
t(4;11)(q21;q23) in ANLL-M4 (secondary), 75:15
t(4;11)(q26;p13) in ANLL-M5 (secondary), 75:15
t(4;12)(p13;p12) in MDS, 74:45
t(4;12)(p16;q15-21) in Warthin tumor, 76:129
t(4;12)(q22;p12) in glioma, 76:88
t(4;12)(q26;q24.32) in glioma, 76:88
t(4;14)(p12;p11) in phyllodes of breast, 78:200
t(4;15)(p15.3;q21) in glioma, 76:88
t(4;16)(q21.2;q23) in glioma, 76:88
t(4;16)(q24;q13) in glioma, 76:88
t(4;16)(q27;q13) in CML, 73:57
t(4;17)(q28;p11) in glioma, 76:88
t(4;18)(p15.1;q12.3) in glioma, 76:88
t(4;21)(p10;q10) in sigmoid adenoma, 74:104
t(4;22)(q11;p11) in sacral chordoma, 73:147
t(4;22)(q35;q11) in Ph+ CML, 73:57
t(5;5)(q14;q32) in glioma, 76:89
t(5;6)(q11;q24) in ovarian cancer, 73:33
t(5;6)(q14;p25) in glioma, 76:88
t(5;6)(q35;p12) in glioma, 76:88
t(5;7)(q13;p15) in hemangiopericytoma, 72:137
t(5;7)(q13;q22) in squamous cell carcinoma of the head and neck, 77:62
t(5;7)(q21;q21) in glioma, 76:89
t(5;7)(q32;q22) in glioma, 76:88
t(5;7)(q33;q36) in sacral chordoma, 73:147
t(5;9;22)(p12;q33;q13.3) in glioma, 76:89
t(5;10)(p13;p14-15) in osteosarcoma, 77:83
t(5;11)(p13;p15) in ANLL-M5 (secondary), 75:17
t(5;11)(q11.2;q23) in malignant melanoma, 77:70
t(5;11)(q12;q25) in glioma, 76:88
t(5;11)(q14;q13.4) in glioma, 76:88
t(5;11)(q21;q25) in glioma, 76:88
t(5;12)(q13;q13) in MDS, 74:45
t(5;12)(q21;q23) in Richter syndrome, 73:65
t(5;12)(q22;q24.2) in Richter syndrome, 73:65
t(5;14)(q14;q21) in glioma, 76:88
t(5;14)(q31 or q32;q12) in glioma, 76:88

t(5;14)(q31;q32) in glioma, 76:88
t(5;15)(q13;q13) in MDS, 74:45
t(5;15;17)(q13;q22;q12) in APL, 72:73
t(5;17)(q11;q11) in myeloid leukemia, 75:16
t(5;17)(q31;p11) in myeloid leukemia (secondary), 75:16
t(5;18)(p14;q12.3) in glioma, 76:88
t(6;6)(p11;q11) in ovarian cancer, 73:33
t(6;6)(q25-27;p21) in uveal melanoma, 72:109
t(6;7)(q13;q13) in T-lymphoma, 78:15
t(6;7)(q24;q34) in ALL, 76:120
t(6;8)(q13-15;q11-13) in uveal melanoma, 72:109
t(6;8;21)(q21;q22;q22) in AML, 75:140
t(6;9)(p11;p11) in ovarian cancer, 73:33
t(6;9)(p21;p24) in uveal melanoma, 72:109
t(6;9;22)(p21;q34;q11) in CML, 73:57
t(6;9)(q11;p11) in sacral chordoma, 75:23
t(6;9)(q23;p22) in lacrimal gland tumor, 75:134
t(6;11)(p21.1;q13) in ANLL-M2 (secondary), 75:17
t(6;11)(q15;p15) in fibrous dysplasia, 77:114
t(6;12)(q25;q13) in chondrosarcoma, 76:104
t(6;13)(p10;q10) in glioma, 76:88
t(6;13)(p12.2;p13) in uveal melanoma, 72:109
t(6;13)(q25;q34) in ovarian cancer, 73:33
t(6;14)(p23;q21-22) in Sézary syndrome, 75:130
t(6;14)(q21;q32) in fibroadenoma of breast, 76:145
t(6;15)(p21;p13) in sacral chordoma,
t(6;15)(p24;q21) in glioma, 76:88
t(6;15)(p25;q22) in Ph+ CML, 72:65
t(6;17)(p11;q12) in glioma, 76:88
t(6;17)(p24;q22) in glioma, 76:88
t(6;17)(q15;q11) in pancreatic cancer, 76:29
t(6;18)(p21;q23) in varicose vein, 75:27
t(6;19)(q16;q13.3) in Ph+ CML, 72:65
t(6;22)(p12;p11) in uveal melanoma, 72:109
t(6;22)(p21;p11) in uveal melanoma, 72:109
t(7;7)(q31;q33) in sigmoid adenoma, 74:104
t(7;8)(q36;q12) in ovarian cancer, 73:33
t(7;9)(p10;p10) in glioma, 76:89
t(7;9)(p11.1;q11) in malignant melanoma, 77:70
t(7;9)(p22;q12) in ovarian cancer, 73:33
t(7;9)(q22;q22) in leiomyoma, 77:65
t(7;11)(p21;q13) in ovarian cancer, 73:33
t(7;11)(q11;q13) in ovarian cancer, 73:33
t(7;12)(p15-21;p12-13) in AML-M1, 73:171
t(7;12)(p15;q15) in hemangiopericytoma, 72:137
t(7;14)(p14;q24.2) in glioma, 76:88
t(7;14)(q11;p11) in ALL, 76:120
t(7;14)(q31;q31) in glioma, 76:89
t(7;15)(p22;q11) in ovarian cancer, 73:33
t(7;16)(p12;p11) in osteosarcoma, 77:83
t(7;17)(p11.2;q11.2) in MDS, 74:45
t(7;17)(p15-21;q12-21) in endometrial stromal sarcoma, 77:45
t(7;18)(p12;p11.3) in malignant melanoma, 77:70
t(7;18)(q11;p11) in sacral chordoma, 75:23
t(7;19)(q21.3;q13) in hibernoma, 72:59
t(7;20)(q22;q13) in varicose vein, 75:27
t(7;21;8)(q32;q22;q22) in ANLL-M2, 75:140
t(8;9)(q11;q34) in lacrimal gland tumor, 75:134
t(8;9)(q11.1;p11) in malignant melanoma, 77:70
t(8;10)(q11;q22) in lacrimal gland tumor, 75:134
t(8;11)(p11;p13) in ALL (L1), 78:23
t(8;11)(q12;p15) in salivary gland tumor, 75:137
t(8;11;21)(q22;q13;q22) in ANLL-M2, 75:14
t(8;12)(q11;q12) in lacrimal gland tumor, 75:134
t(8;12)(q12;p12) in lacrimal gland tumor, 75:134
t(8;13)(p21;q12) in myeloid leukemia (secondary), 75:16
t(8;13)(q13;p11) in uveal melanoma, 72:109
t(8;13)(q13;q22) in salivary gland tumor, 75:137
t(8;13)(q13;q31) in glioma, 75:77
t(8;13;21)(q22;q12;q22) in ANLL-M2, 75:140
t(8;14)(q11.2;q24) in lipoblastoma, 76:39
t(8;14)(q24;q32) in ALL, 76:120
t(8;14;18)(q24;q32;q22) in B-cell line, 74:87
t(8;15)(q22;q24) in pancreatic cancer, 76:29
t(8;15;21)(q22;q21;q21) in ANLL-M2, 75:140
t(8;15;21)(q22;q21;q22) in AML, 75:140
t(8;15;21)(q22;q26;q22) in ANLL-M2, 75:140
t(8;17)(p21;p13) in chondrosarcoma, 76:104
t(8;17)(p21;q21) in APL, 72:75
t(8;17)(q11;p13) in ovarian cancer, 73:33
t(8;17;21)(q22;p11;q22) in ANLL-M2, 75:140
t(8;17;21)(q22;q23;q22) in ANLL-M2, 75:140
t(8;18;21)(q11q22;q23;q22) in ANLL-M2, 75:140
t(8;21)(q12;q11) in osteosarcoma, 77:83
t(8;21)(q22;q22) in ANLL-M2, 75:140
t(8;21)(q22;q22) in ANLL-M2 (secondary), 75:15
t(8;21)(q22;q22) in ANLL with Down syndrome, 76:72
t(8;21)(q22;q22) in MPD, 75:106
t(8;21;5)(q22;q22;q31) in ANLL-M2, 75:140
t(8;21;11)(q22;q22;p15) in ANLL-M2, 75:140
t(8;22)(p11;q11) in salivary gland tumor, 75:137
t(8;22)(q22;q11) in epithelioid sarcoma, 72:151
t(8;22)(q22;q22) in AML (M1), 73:79
t(9;10)(p11;q11) in testicular teratoma, 75:90
t(9;10)(p22;q22) in phyllodes of breast, 78:200
t(9;10;11)(q34;q22;q13) in hibernoma, 72:59
t(9;11)(p21;q23) in ANLL-M4 (secondary), 75:17
t(9;11)(p21;q23) in ANLL-M5 (secondary), 75:15, 16
t(9;11)(p21-22;q23) in ANLL-M4 (secondary), 75:17
t(9;11)(p22;p15) in M1 (biphenotypic), 76:116
t(9;11)(p22;q23) in ANLL-M4 (secondary), 75:16
t(9;11)(p22;q23) in ANLL-M5 (secondary), 75:17
t(9;11)(p22;q23) in CMMoL (secondary), 75:64
t(9;11)(p22;q24) in ANLL-M5 (secondary), 75:15
t(9;11)(q34;q13) in squamous cell carcinoma of the head and neck, 77:62
t(9;12)(q11;p13) in salivary gland tumor, 75:137
t(9;12)(q12;p13) in osteosarcoma, 77:83
t(9;12;22)(q34;q11;q11) in CML, 73:57
t(9;14)(q21;q21) in glioma, 76:89
t(9;15)(q21;p11) in varicose vein, 75:27
t(9;15)(q33;q23) in glioma, 76:89
t(9;16)(q12;p13.3) in glioma, 76:88
t(9;17)(p13;p11.2) in MDS, 74:45
t(9;21)(p22;q22) in ANLL-M4 (secondary), 75:15
t(9;22)(q22;q11) in chondrosarcoma, 76:104
t(9;22;15)(q31;q12.2;q25) in chondrosarcoma, 76:104

t(9;22)(q34;q11) in ALL, 76:120
t(9;22)(q34;q11) in ANLL, 76:70
t(9;22)(q34;q11) in Ph+ CML, 72:65
t(9;22)(q34;q12-13) in rhabdoid tumor, 77:202
t(10;10)(p14;p15) in glioma, 76:88
t(10;11)(p13;q13) in ANLL-M4 (secondary), 75:15
t(10;11)(q26;q13) in MDS (secondary), 75:16
t(10;12)(q11;p11) in osteosarcoma, 77:83
t(10;15)(p15;q22) in adenoid cystic carcinoma, 75:150
t(10;17)(q11;p13) in varicose vein, 75:27
t(10;22)(q11.2;p13) in squamous cell carcinoma of the head and neck, 77:62
t(11;11)(p11;q24) in ovarian cancer, 73:33
t(11;11)(p15;q13) in ovarian cancer, 73:33
t(11;12)(p15.2;q24.2) in glioma, 76:88
t(11;12)(q23;p13) in ANLL-M5 (secondary), 75:16
t(11;12)(q23;q13) in squamous cell carcinoma of the head and neck, 77:62
t(11;13)(q12;q22) in ovarian cancer, 73:33
t(11;14)(p13;q11) in ALL, 76:120
t(11;14)(p14;q23) in ovarian cancer, 73:33
t(11;14)(q13;q32) in multiple myeloma, 74:115
t(11;14)(q13;q32) in Richter syndrome, 73:65
t(11;15;17)(q13;q22;q12) in APL, 72:73
t(11;16)(q13-14;q23) in Warthin tumor, 76:129
t(11;16)(q23;p13) in ANLL-M0 (secondary), 75:15
t(11;16)(q23;p13.3) in ANLL-M2, 75:17
t(11;17)(p11.2;p11.2) in MDS, 74:45
t(11;17)(q13;p13) in MDS, 74:45
t(11;17)(q23;q11-21) in M5 ANLL, 74:50
t(11;17)(q23;q21) in ANLL-M2 (secondary), 75:16
t(11;17)(q23;q25) in ANLL-M5 (secondary), 75:15
t(11;17)(q23;q25) in CMMoL, 75:17
t(11;18)(q24;q12.3) in glioma, 76:88
t(11;19)(q13;p13) in MDS, 75:16
t(11;19)(q14-21;p12) in mucoepidermoid carcinoma, 74:81
t(11;19)(q21;p13.1) in salivary gland tumor, 75:137
t(11;19)(q23;p13) in ANLL-M5 (secondary), 75:16
t(11;19)(q23;p13.1) in ANLL-M2 (secondary), 75:17
t(11;19)(q23;q13) in ANLL-M4 (secondary), 75:15
t(11;21)(q23;q22) in ANLL-M5 (secondary), 75:15
t(11;22)(q24;q12) in Ewing sarcoma, 74:13
t(12;13)(p13;q14) in ALL, 76:120
t(12;13)(p13;q14) in ANLL (M0), 77:106
t(12;13)(q24;q14) in follicular lymphoma, 76:140
t(12;14)(p13;q13) in ovarian cancer, 73:33
t(12;14)(q10;q10) in CLL, 76:159
t(12;14)(q11;q31) in glioma, 76:88
t(12;16)(q15;q24) in adenolipomas, 72:146
t(12;17)(p11;q11) in MDS, 74:45
t(12;17)(p11.2;p11.2) in MDS, 74:45
t(12;17)(q12;q24) in glioma, 75:77
t(12;17)(q15;q12) in hidradenoma, 77:26
t(12;17)(q22;q25) in ANLL-M4 (secondary), 75:16
t(12;19)(q13;q13) in chondrosarcoma, 76;104
t(12;19)(q24;p13) in hidradenoma, 77:26
t(12;22)(p11;q11) in granulocytic sarcoma, 74:59
t(12;22)(p13;q12) in CML, 72:105
t(12;22)(q13-14;q12-13) in CCS, 72:141
t(13;14)(q11;p13) in ovarian cancer, 73:33
t(13;15)(q13;p12) in glioma, 76:88
t(13;17)(q10;q10) in sigmoid adenoma, 74:104
t(13;17)(q11-13;p11) in T-lymphoma, 78:15
t(13;17)(q12;q21) in glioma, 76:88
t(13;19)(q14;p13.3) in glioma, 76:89
t(13;22)(q10;q10) in rectal adenoma, 74:104
t(13;22)(q11;p11) in ovarian cancer, 73:33
t(14;17)(p11;q11) in MDS, 74:45
t(14;17)(p11.2;q22) in glioma, 76:89
t(14;17)(q12;q22 or q23) in glioma, 76:88
t(14;18)(p12;q22) in glioma, 76:89
t(14;18)(q24;q22) in glioma, 76:88
t(14;18)(q32;q21) in ALL (L1), 78:23, 36
t(14;18)(q32;q21) in follicular lymphoma, 76:140
t(14;19)(q32;q13) in follicular lymphoma, 75:72
t(14;20)(q12;q13.3) in glioma, 76:88
t(15;16)(p13;p12) in glioma, 76:88
t(15;17)(q22;q12) in ANLL-M3 (secondary), 75:17
t(15;17)(q25;q22) in glioma, 76:88
t(15;18)(p11;p11) in osteosarcoma, 77:83
t(15;19)(q13;p13.3) in glioma, 76:88
t(15;21)(p11.1;q11.1) in malignant melanoma, 77:70
t(15;21)(p11.1;q11.2) in malignant melanoma, 77:70
t(16;17)(p12;p12) in glioma, 76:89
t(16;18)(q21;p11) in glioma, 76:88
t(16;21)(p11;q22) in ALL, 75:60
t(16;21)(q11;p11) in chondrosarcoma, 76:100, 104
t(16;22)(q24;q11) in Ph+ CML, 73:57
t(17;18)(q11;p11) in pancreatic cancer, 76:29
t(17;18)(q21.1;q22) in glioma, 76:88
t(17;21)(p11;q11) in CLL, 78:108
t(18;20)(q11;p11) in chondrosarcoma, 76:100, 104
t(18;21)(q12;q11-21) in gallbladder cancer, 76:15
t(18;21)(q21;q22) in glioma, 76:88
t(18;22)(p11.1;q11.2) in ovarian cancer, 73:33
t(21;22)(q22;q11) in Ph+ CML, 74:156
t(X;1)(q25;p31) in glioma, 76:89
t(X;1)(q28;q22) in granulocytic sarcoma,74:59
t(X;3)(q24;q11) in sacral chordoma, 73:147
t(X;3)(q25-26;p13-14) in renal cell carcinoma, 77:1
t(X;5)(q13;p13) in glioma, 76:89
t(X;8)(q26;q21.3) in mastocytosis, 78:236
t(X;10)(p11;p11) in ANLL-M2 (secondary), 75:17
t(X;10)(p22;q23) in Merkel cell carcinoma, 75:74
t(X;11)(q13;q23) in ANLL-M4 (secondary), 75:15
t(X;12)(q28;q13) in varicose vein, 75:27
t(X;18)(p11.2;q11.2) in synovial sarcoma, 73:89
t(Y;9)(q11;q34) in CML, 73:57
t(Y;15)(q11;p13) in neuroblastoma, 74:30
variant Ph translocations, 73:57
variant t(8;21) in M2, 75:139
Treatment-related leukemia; see Secondary leukemia
Trisomy
in gliomas, 75:77
single trisomies in tumors, 73:50
1q in large cell lymphoma, 77:91
7 and 10 in bladder cancer, 77:118

+2 in proliferative myositis, 76:157
+5 in ALL, 75:116
+5 in salivary gland tumor, 76:96
+5 in marrow cultures of patients with cancer, 78:207
+6 as sole anomaly in myeloid disorders, 74:150
+7 in endometrial cancer, 73:142
+7 in gliomas, 72:55
+7 in ovarian cancer, 73:33
+8 in ALL, 74:144; 75:6
+8 in CCS, 72:141
+8 in GSS, 72:96
+8 in Ph+ CML, 72:24
+11 in AMMoL, 77:33
+11 in congenital mesoblastic nephroma, 77:50
+11 (+8,+10) in fibrosarcoma, 78:82
+12 in CLL, 72:83
+14 in ANLL, 72:86
+18 in medullary breast cancer, 73:75
+19 in hematologic neoplasms, 74:62
+21 in megakaryoblastic leukemia, 74:66
Trophoblastic tumors
genetic origin, 73:95
malignant, 73:95
Tumors
adipose, 72:59, 146
allelotype in pediatric tumors, 77:150
bone tumors, 78:115
brain, 73:46; 75:77
centromeric breakpoints, 77:165
chromosome 18 and metastases, 77:177
clonal evolution in bone and soft tissue tumors, 77:203
cyclin D1 in tumors, 77:154
cytogenetics of, 77:203, 204; 78:115
cytogenetics of soft tissue tumors, 77:203; 78:115
DNA fingerprint analysis, 77:183
embryonic: origin, 78:242
endocrine of pancreas, 77:5
fine needle aspirations of soft tissue tumors, 77:203
genitourinary in families, 72:28
germ cell, 73:11, 53; 75:90
gliomas, 72:55, 130; 73:46, 122
in von Hippel-Lindau syndrome, 77:1
karyotypic clonality in epithelial tumors, 77:159
method, cytogenetic, 72:161; 76:77
methodology and cytogenetics, 76:77
methylation mapping, 77:150
models, 76:77
ovarian, 73:33, 60
pancreatic, 77:55
pathology and cytogenetics, 78:115
pediatric tumors, 77:204
phenotypic variability in +8, 76:158
renal, 72:28; 73:134
trisomy in, 76:158
trophoblastic, 73:95
+8 in, 76:158
Turcot syndrome
glioma polyposis, 77:180

Ureter
cytogenetics of cancer, 77:194
Urogenital tumors
DNA analysis, 77:166
Uterine
adenocarcinoma with chromosome 1 change, 78:105
cervical lesions, 75:120
cervix, carcinoma, 74:153
chromosome 1 in adenocarcinoma, 78:105
cytogenetics endometriosis, 78:172
endometrial cancer line (murine), 74:99
endometriosis, 78:172
leiomyomas, 74:19; 77:65
leiomyosarcoma, 74:19
tumor cytogenetics (FISH), 74:19
Uveal melanoma
CGH in melanoma, 77:163
clinical correlations in melanoma, 72:109
cytogenetics of melanoma, 72:109; 77:144
LOH of chromosome 3, 77:183
melanoma, 72:109; 77:144
two subclones, 77:144

Veins
cytogenetic changes in varicose, 75:26
varicose, 75:26
Virus
EB virus, 77:167
integration sites in chromosomes, 72:39
papillomavirus and p53, 77:178
papillomavirus-immortalized cell lines, 72:39
Rous sarcoma virus transformation, 74:123
von Hippel-Lindau syndrome (VHL)
chromosome changes in tumors, 77:1
cytogenetics, 77:1
FISH studies, 77:1
hemangioblastoma in, 77:1
pheochromocytoma in, 77:1
renal cell carcinoma in, 77:1
tumors in, 77:1
tumor suppressor gene, 77:153

Waldenström Macroglobulinemia
IL4 gene in, 75:153
karyotype, 73:169
14q+ marker, 73:169
Warthin tumor; see Cystadenolymphoma
Wiedemann-Beckwith syndrome
associated tumors, 77:152
Wilms tumor and LOH, 77:167
11p and childhood tumors, 77:168
11p15 in, 77:168
Wilms tumor
chromosome 7 in, 77:93
chromosome 12 in, 77:198
cytogenetics of, 77:199
FISH vs. cytogenetics, 77:198
germline and somatic abnormalities of chromosome 7, 77:93
leukemia and lymphoma in families of children with

Wilms tumor, 77:129
molecular aberrations, 77:168
tumors in families, 77:129
11p in, 77:198

X chromosome
change in tumors, 72:160
in synovial sarcoma, 73:89
inv(X) in hemangiopericytoma, 72:137
loss in ANLL, 72:44
loss in brain tumors, 73:46; 75:77
loss in ovarian cancer, 73:33
probes in MRD and BMT, 73:130
sole change in ANLL, 72:44
+X in large cell lymphoma, 77:91

Y chromosome
change in tumors, 72:160
in ANLL, 76:70
loss in ANLL, 72:44
loss in brain tumors, 73:46; 75:77
probes in MRD and BMT, 73:130
sole change in ANLL, 72:44
Yeast Artificial Chromosomes (YAC)
method for isolation, 77:151